NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02621606,[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001),https://clinicaltrials.gov/study/NCT02621606,,COMPLETED,"The purpose of this open-label, 3-part study is to investigate the safety and efficacy of \[11C\]MK-6884 as a positron emission tomography (PET) imaging agent for quantifying muscarinic 4 (M4) positive allosteric modulator (PAM) receptor density in brain regions of interest. The study will enroll healthy participants (Parts 1 and 2) and participants with Alzheimer's Disease (AD) (Part 3). The primary efficacy hypothesis is that the average intra-subject test-retest (T-RT) variability of tracer uptake in brain regions of interest is â‰¤20%.",YES,Alzheimer's Disease,DRUG: [11C]MK-6884,"Number of Participants Experiencing an Adverse Event (AE), The number of participants experiencing an adverse event (AE) was assessed. An AE is defined as any unfavorable and unintended medical occurrence, sign, symptom, or disease temporally associated with the use of a pharmaceutical product or protocol-specified procedure, whether or not considered related to the pharmaceutical product or protocol-specified procedure. Any worsening of a preexisting condition, temporally associated with the use of the Sponsor's product, is also an AE., Up to 15 days|Number of Participants Discontinuing the Study Due to an Adverse Event (AE), The number of participants discontinuing the study due to an AE was assessed. An AE is defined as any unfavorable and unintended medical occurrence, sign, symptom, or disease temporally associated with the use of a pharmaceutical product or protocol-specified procedure, whether or not considered related to the pharmaceutical product or protocol-specified procedure. Any worsening of a preexisting condition, temporally associated with the use of the Sponsor's product, is also an AE., Up to 15 days|[Part 1] Mean Effective Dose of [11C]MK-6884, Mean effective dose (ED) of \[11C\]MK-6884 was calculated as a measure of risk associated with exposure of the whole body (WB) to low levels of ionizing radiation. Following \[11C\]MK-6884 injection, WB positron emission tomography (PET) scans were collected to visually identify organs absorbing \[11C\]MK-6884 in significant amounts. Around identified organs, three-dimensional (3D) volumes were drawn to estimate the percentage of injected activity absorbed. These data were converted into time-activity curves (TACs) and retention of radioactivity in these regions was entered into a human biodistribution model to determine ED of \[11C\]MK-6884. ED is expressed in units millisieverts (mSv) / MBq., Up to 2 hours post-dose|[Part 1] Mean Organ Effective Dose of [11C]MK-6884, Mean organ ED of \[11C\]MK-6884 was calculated as a measure of risk associated with exposure of individual organs to low levels of ionizing radiation. Following \[11C\]MK-6884 injection, WB PET scans were collected to visually identify organs absorbing \[11C\]MK-6884 in significant amounts. Around identified organs, 3D volumes were drawn to estimate the percentage of injected activity absorbed. These data were converted into TACs and retention of radioactivity in these regions was used to calculate organ-specific ED of \[11C\]MK-6884. For sex organs (testes/ovaries), organ EDs were derived for participants of the respective sex. However, organ ED for the uterus was estimable in all participants as the male radiologic phantom was sufficiently hermaphroditic., Up to 2 hours post dose|[Part 2] Mean Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest (ROI), Mean BPND of \[11C\]MK-6884 in each brain ROI was assessed. BPND is the ratio at equilibrium of specifically bound \[11C\]MK-6884 to that of non-displaceable \[11C\]MK-6884 in tissue. At time ""0"", a single IV bolus of \[11\]MK-6884 is administered and PET scanning initiated, yielding brain regional TACs. These TACs are then used to determine peak standard uptake value (SUV) and area under the curve (AUC) in order to quantify brain regional \[11C\]MK-6884 uptake. The target region BPND is estimated using the cerebellum as the reference region with the transient equilibrium tissue ratio (TE-TR) method. Higher values indicate increased specific \[11C\]MK-6884 binding in the brain ROI., Up to 90 minutes post dose|[Part 2] Intra-subject Test-Retest (T-RT) Variability of Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest (ROI), Intra-subject T-RT variability in BPND of \[11C\]MK-6884 in each brain ROI was assessed. For each healthy elderly participant receiving 2 doses of \[11C\]MK-6884 in study Part 2, the BPND calculated during the first dose (BPND-1) was compared to the BPND calculated during the second dose (BPND-2) to determine the percent T-RT variability of the BPND of \[11C\]MK-6884 for each brain ROI.

Percent T-RT variability = \[absolute value (BPND-1 - BPND-2) / (average BPND)\] \* 100. A percent T-RT variability = 0, indicates no variability between BPND-1 and BPND-2., Up to 24 hours post dose|[Part 3] Mean Regional Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest, Mean BPND of \[11C\]MK-6884 in each brain ROI was assessed. BPND is the ratio at equilibrium of specifically bound \[11C\]MK-6884 to that of non-displaceable \[11C\]MK-6884 in tissue. At time ""0"", a single IV bolus of \[11\]MK-6884 is administered and PET scanning initiated, yielding brain regional TACs. These TACs are then used to determine SUV and AUC in order to quantify brain regional \[11C\]MK-6884 uptake. The target region BPND is estimated using the cerebellum as the reference region with the TE-TR method. Higher values indicate increased specific \[11C\]MK-6884 binding in the brain ROI., Up to 90 minutes post dose",,,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE1,20,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,6884-001|MK-6884-001|2015-001631-20,2016-01-08,2017-12-28,2017-12-28,2015-12-03,2018-09-28,2022-09-13,,"Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/06/NCT02621606/Prot_SAP_000.pdf"
NCT03419052,MINDSpeed Food and Brain Training RCT,https://clinicaltrials.gov/study/NCT03419052,MINDSpeed,ACTIVE_NOT_RECRUITING,The purpose of this study is to learn how foods high in polyphenols and brain training exercises affect older adults' cognitive performance,NO,Low Education|Cognition|Cognitive Training|Polyphenols,BEHAVIORAL: Speed of processing training|BEHAVIORAL: MIND foods|BEHAVIORAL: Cognitive training control|BEHAVIORAL: Control foods,"Executive Cognitive Function Composite Score, Executive Cognitive Function Composite Score as Measured by Individually-Administered Tests of Verbal Fluency, Complex Sequencing, Response Inhibition, and List Learning. The scale score range is -20 to 20. Low scores represent worse function and higher scores represent better function., Immediately following the 12-week intervention (Immediate Post-Training)]",,,Indiana University,National Institutes of Health (NIH)|National Institute on Aging (NIA),ALL,"ADULT, OLDER_ADULT",NA,212,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",1703766063|R01AG052439,2019-01-10,2024-03-07,2024-03-07,2018-02-01,,2024-02-08,"Regenstrief Institute, Indianapolis, Indiana, 46202, United States","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/52/NCT03419052/ICF_000.pdf"
NCT04394845,A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants,https://clinicaltrials.gov/study/NCT04394845,,COMPLETED,"The purpose of this study is to evaluate the biodistribution, safety and tolerability of a single dose of \[18F\]GTP1 as a tau targeted radiopharmaceutical in healthy Japanese participants.",YES,Alzheimer Disease,DIAGNOSTIC_TEST: [18F]GTP1,"Total Source Organ Counts Based on Individualized Organ Volumes of Interest (VOIs), Decay corrected \[18F\]GTP1 time-activity in the source organs acquired following bolus tracer injection and expressed as %Injected Dose (ID)., Day 1|Source Organ Residence Time (Total Number of Disintegrations), Source organ uptake and washout with calculation of total number of disintegrations (or residence time, or kinetic values) using the area under the time-activity curve divided by the injected dose of radiopharmaceutical, Day 1|Mean Radiation Absorbed Dose Estimates in Target Organs and Whole Body Based on Standard Medical Internal Radiation Dose (MIRD) Methodology, Radiation absorbed dose estimates based on the Medical Internal Radiation Dose (MIRD) methodology utilizing urine data and International Commission on Radiological Protection (ICRP) gastrointestinal (GI) tract kinetics, Day 1|Percentage of Participants With Adverse Events, An AE is the appearance or worsening of any undesirable sign, symptom, or medical condition, even if the event is not considered to be related to study drug. Study drug includes the investigational drug under evaluation during any phase of the study. Medical conditions/diseases present before starting study drug are only considered AEs if they worsen after starting study drug. Abnormal laboratory values or test results constitute AEs only if they induce clinical signs or symptoms, are considered clinically significant, or require therapy., Up to 5 days",,,"Genentech, Inc.",Invicro,ALL,"ADULT, OLDER_ADULT",PHASE1,6,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,GN42043,2020-08-11,2020-10-09,2020-10-09,2020-05-19,2021-10-05,2021-11-03,"Invicro, a Konica Minolta company, New Haven, Connecticut, 06510, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/45/NCT04394845/Prot_SAP_000.pdf"
NCT03475316,Movement Intervention for Memory Enhancement,https://clinicaltrials.gov/study/NCT03475316,MIME,COMPLETED,"Dancing is a complex sensorimotor rhythmic activity that integrates cognitive, physical, and social components and is applicable to seniors with various fitness levels. Despite its popularity, there is a paucity of studies that have systematically examined the role of dancing in preventing or delaying cognitive decline in older adults at high risk for Alzheimer's disease and related dementias. This preliminary randomized clinical trial will help provide the evidence base to develop a definitive full-scale trial to support or refute prescription of social dancing to prevent further cognitive decline in older adults at high risk of Alzheimer's disease and related dementia.",YES,"Alzheimer Disease|Dementia|Cognitive Decline|Cognitive Impairment|Dementia, Alzheimer Type",BEHAVIORAL: Social Dancing|BEHAVIORAL: Treadmill Walking,"Executive Function (EF)., Improvement in EF will be measured through a composite score from 3 tests. (1) The Digit Symbol Substitution test is a measure of attention and speed of processing. Scoring is based on the total number of correct responses generated over 90 seconds. Higher values reflect better outcome. (2) Flanker Test is a measure of speed of processing, attention and inhibitory control. Scoring is based on accuracy and reaction time. Lower values reflect better outcome. (3) Walking While Talking (repeating alternating letters of the alphabet) gait speed (centimeters/second) will be measured using a electronic walkway system. Higher values reflect better outcome. The scores on the 3 tests are standardized and summed to obtain a single z-score. The Z-score indicates the number of standard deviations away from the mean of the study population and a value of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean., Baseline, 6 months","Neuroplasticity., Functional Magnetic Resonance Imaging will be used to investigate neuroplasticity under three conditions: 'imagined Walking While Talking' task, Digit Symbol Substitution test and Flanker interference tests. Functional activation/deactivation patterns recorded by Functional Magnetic Resonance Imaging in response to the three tests will be examined within each participant before and after the intervention. The values measured as factor scores reflect change in functional activation/deactivation covariance patterns from pre to post intervention as a function intervention (social dancing vs. treadmill walking). Larger absolute values reflect more change in functional activation/deactivation covariance patterns from pre to post intervention on each of the three tasks. There is no set minimum and maximum values of the scale., Baseline, 6 months","Lifestyle Changes., Lifestyle changes will be measured at baseline and post-intervention through the Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire. CHAMPS scale measures weekly frequency/week of moderate-intensity exercise-related activities. Scores range from 0 to 133 with higher score indicating more exercise, Baseline, 6 months|Gait., Changes in gait speed will be measured at baseline and post-intervention through a quantitative gait mat. Gait is measured in centimeters per second and higher values indicate faster walking speed., Baseline, 6 months|Balance, Changes in balance will be measures at baseline and post-intervention using the Unipedal stance (measured in seconds). Higher time indicates better balance., Baseline, 6 months|Modified Katz Disability Scale., Changes in function assessed by 4 key activities of daily living tasks-bathing, dressing, walking, and transferring. Scores range from 0 to 8 with higher scores indicating worse outcome., Baseline, 6 months|The Geriatric Depression Scale (GDS)., Changes in depressive symptoms assessed using the 30 item GDS, scores range from 0 (not depressed) to 30 (depressed)., Baseline, 6 months",Albert Einstein College of Medicine,National Institute on Aging (NIA),ALL,OLDER_ADULT,NA,25,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2018-8942|1R21AG057586-01A1,2019-03-28,2020-06-30,2020-06-30,2018-03-23,2021-05-04,2021-08-16,"Albert Einstein College of Medicine, Bronx, New York, 10461, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/16/NCT03475316/Prot_SAP_000.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/16/NCT03475316/ICF_001.pdf"
NCT03124550,Development of An Exergame for Caregivers of Individuals With Alzheimer's Disease or Related Dementias,https://clinicaltrials.gov/study/NCT03124550,,COMPLETED,"The study goal is to evaluate user experience with our developed exergame, which was designed to increase physical activity, exercise self-efficacy, and social connections among caregivers of individuals with Alzheimer's disease (AD) or related dementias. Participants will use this garden-themed exergame for six weeks. Tailoring an exergame for caregivers of AD or related dementias has the potential to increase physical activity and to improve overall health and well-being in this vulnerable population, which in turn can benefit the patients for whom they provide care. All study sessions be held at a location convenient to participants.",YES,"Sedentary Lifestyle|Stress, Psychological",BEHAVIORAL: Exergame Experience,"Number of Steps, Number of steps recorded daily from the Fitbit, weekly step averages, Daily for six weeks","Caregiver's Management of Distress, Caregiver's management of distress was measured with the amount of time caregivers spent on themselves doing leisure activities when they were under stress from caregiving. Answer choices ranged from never (1) to very often (4). A higher score indicated better management of distress., Baseline (pretest) and 6 weeks from the start of the intervention (posttest)|Exercise Self-efficacy, A modified version of Bandura's Exercise Self-Efficacy scale (Bandura, 1997) was used in the current study. This 8-item scale assesses how sure one is that they would exercise under different conditions or constraints (e.g. How sure are you that you will exercise when you are feeling down or depressed?), with answer choices ranging from not sure at all (1) to very sure (4). The 8 items are averaged to create a composite score, where a higher score indicates greater exercise self-efficacy (Neupert et al., 2009)., Baseline (pretest) and 6 weeks from the start of the intervention (posttest)|Number of Social Contacts, Average daily number of social contacts with other caregivers using the exergame in a week, Daily for six weeks",,Brandeis University,National Institute on Aging (NIA),ALL,"ADULT, OLDER_ADULT",NA,18,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,Exergame #17065|5P30AG048785,2017-05-11,2019-08-06,2019-09-20,2017-04-24,2020-08-17,2020-10-22,"Northeastern University, Boston, Massachusetts, 02115, United States","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/50/NCT03124550/ICF_000.pdf|Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/50/NCT03124550/Prot_SAP_001.pdf"
NCT03422250,Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia,https://clinicaltrials.gov/study/NCT03422250,NetCogBs,COMPLETED,"This pilot study aims to test clinical and connectivity changes following non-invasive stimulation of disease-specific networks in Alzheimer's disease (AD) and behavioral variant frontotemporal dementia (bvFTD). Brain network stimulation will be carried out with transcranial direct current stimulation (tDCS). Target networks will be the default mode network (DMN) and salience network (SN). Twenty AD and 20 bvFTD patients will be recruited and assessed with a comprehensive clinical, behavioral and cognitive battery, and 3 Tesla MRI scan (including resting-state functional MRI, arterial spin labeling, diffusion tensor imaging, structural MRI) at three time-points: baseline, after tDCS, and after 6 months. Patients will be randomized to 2 arms: anodal stimulation of the disease-specific network (DMN in AD, SN in bvFTD) or cathodal stimulation of the anti-correlated network (SN in AD, DMN in bvFTD). The intervention will consist of 10 tDCS sessions over two weeks. Cerebrospinal fluid (CSF) samples will be collected at baseline for biomarker's assessment; blood samples will be collected at each time-point to assess changes in peripheral inflammatory markers. Blood and CSF collection will be optional. A sample of 20 elderly controls will be included for baseline comparisons.",YES,"Alzheimer's Disease|Frontotemporal Dementia, Behavioral Variant",DEVICE: transcranial direct current stimulation (tDCS),"Change in Clinical Disease Severity (CDR), CDR - Clinical Dementia Rating score

The clinical dementia rating (CDR) is a clinical global rating scale administered to both the participant and the caregiver, assessing 6 domains of participant function: memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care. Each domain is based on a 5-point scale ranging from no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 to severe impairment=3. The global CDR score is computed via a memory-weighted averaging algorithm of the six domain scores and ranges from 0 to 5. The CDR-sum of boxes (CDR-SB) is the sum of the individual domain scores and ranges from 0 to 18. Higher scores indicate more clinical impairment. Negative changes at post tDCS compared to baseline represent an improvement on the scale., Baseline, post tDCS (week 3)|Change in Behavioral Symptom Severity (NPI), The Neuropsychiatric Inventory (NPI) is a behavioral scale administered to the caregiver assessing 12 dimensions: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor activity, nighttime behaviors, and appetite/eating. Each dimension has multiple screening questions relating to symptoms. If the answer to the screening questions is ""Yes"", the dimensional-score is the product of frequency (1=occasionally to 4=very frequently) and severity (1=Mild to 3=Severe) of symptoms. Dimensional-scores are summed (from 0 to 144). Higher scores indicate greater behavioral disturbances. Negative changes at post tDCS compared to baseline represent an improvement on the scale., Baseline, post tDCS (week 3)|Change in Behavioral Symptom Severity (FBI), The Frontal Behavioral Inventory (FBI) is a 24-item inventory designed to assess behavior and personality changes via caregiver. Item-level scores range from 0=none, 1=mild/occasional, 2=moderate, 3=severe/most of the time. Item-scores are summed (from 0 to 72). Higher scores indicate greater behavioral/personality disturbances. Negative changes at post tDCS compared to baseline represent an improvement on the scale., Baseline, post tDCS (week 3)|Change in Functional Connectivity, Default mode network (DMN) and salience network (SN) mean functional connectivity is assessed on resting state functional MRI. Functional connectivity is standardized to Z scores and thresholded at Z\>2. Higher values denote greater functional connectivity. A positive change at post tDCS compared to baseline represents an increase in resting-state functional connectivity., Baseline, post tDCS (week 3)|Change in Cerebral Blood Flow, Default mode network (DMN) and salience network (SN) mean cerebral blood flow is assessed on arterial spin labeling. Cerebral blood flow is computed by averaging values across the DMN and SN regions of interest. Cerebral blood flow is a measure of brain perfusion, higher values denoting higher perfusion. A positive change at post tDCS compared to baseline represents an increase in perfusion., Baseline, post tDCS (week 3)","Change in Cognition: Memory, The composite memory score consists of the averaged Z-standardized scores of 5 memory tests: immediate and delayed auditory verbal learning test recall, Rey-Osterrieth complex figure recall, story recall, digit span backward and forward tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better memory performance. Positive changes at post tDCS compared to baseline represent an improvement in memory., Baseline, post tDCS (week 3)|Change in Cognition: Language, The composite language score consists of the averaged Z-standardized scores of 2 language tests: verbal fluency and token tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better language performance. Positive changes at post tDCS compared to baseline represent an improvement in language., Baseline, post tDCS (week 3)|Change in Cognition: Executive Function, The composite executive function score consists of the averaged Z-standardized scores of 2 executive functions tests: trail making test part A and part B tests. Each test score is normalized to an independent dataset of healthy controls and inverted. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better executive function performance. Positive changes at post tDCS compared to baseline represent an improvement in executive functions., Baseline, post tDCS (week 3)|Change in Cognition: Visuospatial Function, The visuospatial function score consists of the Z-standardized scores for the Rey-Osterrieth complex figure copy test. Scores are normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better visuospatial performance. Positive changes at post tDCS compared to baseline represent an improvement in visuospatial functions., Baseline, post tDCS (week 3)|Change in Cognition: Emotion Recognition, The composite emotion recognition score consists of the averaged Z-standardized scores for 2 emotion recognition tests: reading the Mind in the Eyes and 60 Ekman faces tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better emotion recognition performance. Positive changes at post tDCS compared to baseline represent an improvement in emotion recognition., Baseline, post tDCS (week 3)|Change in Structural Connectivity: FA, Fractional anisotropy (FA) is assessed on diffusion weighted imaging. FA values are averaged in default mode network (DMN) and salience network (SN) regions of interest. FA values denote the directionality of water diffusivity, ranging from 0 (isotropic diffusion) to 1 (anisotropic diffusion). Higher values denote higher directionality and connectivity. Positive changes at post tDCS compared to baseline represent an improvement in the measure., Baseline, post tDCS (week 3)|Change in Structural Connectivity: MD, AxD, RaD, Mean diffusivity (MD), axial diffusivity (AxD), and radial diffusivity (RaD) are assessed on diffusion weighted imaging. MD, AxD, RaD values are averaged in default mode network (DMN) and salience network (SN) regions of interest. MD, AxD, and RaD measure water diffusion and are expressed in mm\^2/s (starting from 0 with no maximum value; scaled at x10\^-3). Higher values denote higher diffusion and lower connectivity. Negative changes at post tDCS compared to baseline represent an improvement in the measure., Baseline, post tDCS (week 3)",,IRCCS Centro San Giovanni di Dio Fatebenefratelli,,ALL,"ADULT, OLDER_ADULT",NA,45,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",GR-2011-02349787,2015-06-08,2018-11-03,2018-11-03,2018-02-05,2021-03-03,2021-05-19,"IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, 25125, Italy","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/50/NCT03422250/Prot_SAP_000.pdf"
NCT03828383,In-Home Technology for Dementia Caregivers,https://clinicaltrials.gov/study/NCT03828383,,COMPLETED,"This study aims to develop and evaluate in-home assistive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease and frontotemporal dementia.",YES,Dementia|Alzheimer's Disease|Frontotemporal Dementia,DEVICE: In-home technology|DEVICE: Limited in-home technology,"Zarit Burden Interview-Short Form, Questionnaire to measure caregiver burden (Zarit, Reever, \& Bach-Peterson, 1980). 12 items are rated on 0-4 scale. Range: 0-48. No subscales. Higher scores represent worse outcomes., 9 months after baseline|Center for Epidemiological Studies Depression Scale (CES-D), Questionnaire to measure depression (Radloff, 1977). 20 items are rated on a 0-3 scale and summed (range = 0-60). There are no subscales. Higher scores represent worse outcomes. The clinical cut-off is usually set at a score of 16., 9 months after baseline|Beck Anxiety Inventory (BAI), Questionnaire to measure anxiety (Beck, Epstein, Brown, \& Steer, 1988). 20 items are rated on a 0-3 scale and summed (range= 0-60). Higher scores indicate worse outcomes. There are no subscales. A score greater than 36 is considered to be clinically significant., 9 months after baseline|Satisfaction With Life Scale, Questionnaire measuring overall life satisfaction and well-being (Diener, Emmons, Larsen, \& Griffin, 1985). 5 items scored on a 1-7 scale and summed (Range = 5-35). Lower scores indicate worse outcomes. A score of 20 is considered neutral with higher scores considered increasingly more satisfied and lower scores considered increasingly more dissatisfied., 9 months after baseline",,,"University of California, Berkeley","University of California, San Francisco|People Power Company|National Institute on Aging (NIA)",ALL,"ADULT, OLDER_ADULT",NA,78,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,R44AG059458|R44AG059458,2019-02-26,2020-11-27,2020-11-27,2019-02-04,2022-03-09,2022-05-10,"University of California, Berkeley, Berkeley, California, 94720, United States|Los Angeles County, Los Angeles, California, 90011, United States|Orange County, Orange, California, 92856, United States|Clark County, Las Vegas, Nevada, 89108, United States|Oregon, Bend, Oregon, 97701, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/83/NCT03828383/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/83/NCT03828383/SAP_001.pdf"
NCT04200911,"Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway",https://clinicaltrials.gov/study/NCT04200911,CARPE_DIEM,COMPLETED,"Evaluation of central nervous system penetration of orally administered Rapamune (RAPA) in older adults with Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD) and investigate associated safety, tolerability, target engagement, cognition, and functional status as initial proof-of-concept study",YES,"Cognitive Impairment, Mild|Alzheimer Disease",DRUG: Rapamune,"Blood Brain Barrier Penetration of RAPA, Lumbar punctures will be performed at baseline and after the final RAPA dose, to assess CSF levels of the drug. Change is calculated as value at 8 weeks minus the value at baseline., Change from Baseline to 8 weeks","Adverse Events, Number of adverse events experienced across all 10 subjects after they were enrolled and randomized to treatment, regardless of relatedness to intervention., Baseline to 8 weeks|Change in CSF A Beta-42 Levels From Baseline to 8 Weeks, Evaluation of relevant AD biomarkers.Change is calculated as value at 8 weeks minus the value at baseline., Baseline to 8 weeks|Electronic Gait Mapping, Assessment of physical functioning under single and dual task conditions, Change from Baseline to 8 weeks|Grip Strength, Assessment of physical function using grip strength, Change from Baseline to 8 weeks|Clinical Dementia Rating (CDR) Global Score, A 5 point scale used to characterize six domains of cognitive and functional performance to give a possible score of 0-18. Each domain is rated on a score of 0 to 3 (0, 0.5, 1, 2 or 3) and the global score is derived based on the Washington University logarithm. Higher scores indicate worse cognitive and functional status., Change from Baseline to 8 weeks|Benson Figure Copy, A scale used to score a test of visuoconstructional abilities. Scores range from 0-16 with higher scores indicating better performance. Change is calculated as performance at 8 weeks minus baseline., Change from Baseline to 8 weeks|Neuropsychiatric Inventory (NPI), A scale to assess dementia-related behavioral symptoms. The score represents the sum of 12 items, each scored 0-3. The total score can range from 0 to 36. Higher scores indicated greater neuropsychiatric severity. Change is calculated as the 8-week score minus baseline., Change from Baseline to 8 weeks|Functional Activities Questionnaire (FAQ), An informant rates the subject's ability using a scoring system. The measure consists of 10 items with scoring ranging from 0-3 and the total score represents the sum of the items. The scores range from 0 to 30 with higher scores indicating more functional impairment. Change is calculated as the 8-week score minus baseline., Change from Baseline to 8 weeks",,The University of Texas Health Science Center at San Antonio,National Center for Advancing Translational Sciences (NCATS),ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,HSC20190850H|UL1TR002645,2020-06-01,2022-01-13,2022-01-13,2019-12-16,2023-01-27,2023-12-22,"UTHSA McDermott Clinical Sciences Building, San Antonio, Texas, 78229, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/11/NCT04200911/Prot_SAP_000.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/11/NCT04200911/ICF_001.pdf"
NCT04206670,In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment,https://clinicaltrials.gov/study/NCT04206670,,COMPLETED,"This study aims to develop and evaluate new in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias, or mild cognitive impairment.",YES,Dementia|Mild Cognitive Impairment|Alzheimer Disease,DEVICE: In-Home Technology System and Questionnaires|DEVICE: Waiting Control In-Home Technology System and Questionnaires,"3 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D), Questionnaire to measure depression (Radloff, 1977). 20 items are rated on a 0-3 scale and summed (range = 0-60). There are no subscales. Higher scores represent worse outcomes. The clinical cut-off is usually set at a score of 16., 3 months after baseline|6 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D), Questionnaire to measure depression (Radloff, 1977). 20 items are rated on a 0-3 scale and summed (range = 0-60). There are no subscales. Higher scores represent worse outcomes. The clinical cut-off is usually set at a score of 16., 6 months after baseline|3 Months Assessment for Zarit Burden Interview-Short Form, Questionnaire to measure caregiver burden (Zarit, Reever, \& Bach-Peterson, 1980). 12 items are rated on 0-4 scale. Range: 0-48. No subscales. Higher scores represent worse outcomes., 3 months after baseline|6 Months Assessment for Zarit Burden Interview-Short Form, Questionnaire to measure caregiver burden (Zarit, Reever, \& Bach-Peterson, 1980). 12 items are rated on 0-4 scale. Range: 0-48. No subscales. Higher scores represent worse outcomes., 6 months after baseline|3 Months Assessment for Beck Anxiety Inventory (BAI), Questionnaire to measure anxiety (Beck, Epstein, Brown, \& Steer, 1988). 20 items are rated on a 0-3 scale and summed (range= 0-60). Higher scores indicate worse outcomes. There are no subscales. A score greater than 36 is considered to be clinically significant., 3 months after baseline|6 Months Assessment for Beck Anxiety Inventory (BAI), Questionnaire to measure anxiety (Beck, Epstein, Brown, \& Steer, 1988). 20 items are rated on a 0-3 scale and summed (range= 0-60). Higher scores indicate worse outcomes. There are no subscales. A score greater than 36 is considered to be clinically significant., 6 months after baseline|3 Months Assessment for Satisfaction With Life Scale, Questionnaire measuring overall life satisfaction and well-being (Diener, Emmons, Larsen, \& Griffin, 1985). 5 items scored on a 1-7 scale and summed (Range = 5-35). Lower scores indicate worse outcomes. A score of 20 is considered neutral with higher scores considered increasingly more satisfied and lower scores considered increasingly more dissatisfied., 3 months after baseline|6 Months Assessment for Satisfaction With Life Scale, Questionnaire measuring overall life satisfaction and well-being (Diener, Emmons, Larsen, \& Griffin, 1985). 5 items scored on a 1-7 scale and summed (Range = 5-35). Lower scores indicate worse outcomes. A score of 20 is considered neutral with higher scores considered increasingly more satisfied and lower scores considered increasingly more dissatisfied., 6 months after baseline",,,"University of California, Berkeley","People Power Company|National Institute on Aging (NIA)|University of California, San Francisco",ALL,"ADULT, OLDER_ADULT",NA,216,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,R44AG059458-03|R44AG059458,2020-03-10,2021-12-08,2021-12-08,2019-12-20,2022-03-09,2022-05-10,"University of California, Berkeley, Berkeley, California, 94720, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/70/NCT04206670/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/70/NCT04206670/SAP_001.pdf"
NCT03665909,A Proactive Health Monitoring Intervention for Dementia Caregivers,https://clinicaltrials.gov/study/NCT03665909,,COMPLETED,"The objective of this 5-year demonstration project is to build on the work of The Lutheran Home Association (TLHA) and conduct an embedded experimental mixed methods evaluation to determine the efficacy of the eNeighbor technology in improving outcomes among persons with Alzheimer's disease or related dementias (ADRD) living in the community and their family caregivers. The Specific Aims are as follows: 1) To compare 100 ADRD caregivers randomly assigned to an attention control with 100 ADRD caregivers who utilize eNeighbor over an 18-month period to determine if the use of the remote sensor technology results in a) significant (p \< .05) increases in caregiver self-efficacy and sense of competence, b) significant decreases in caregiver distress (subjective stress, depressive symptoms), c) significant delays of or reductions in negative health transitions (falls, wandering events) and service utilization (residential care placement, hospitalizations) for persons with ADRD; and d) greater cost-effectiveness; 2) To determine through ""embedded"" qualitative data collection components how eNeighbor is successfully utilized and why this health monitoring technology benefits persons with ADRD and their family caregivers; and 3) To engage stakeholders on a quarterly basis throughout this 5-year demonstration project in order to enhance the utility and stakeholder-relevance of health monitoring technology for families who care for persons with ADRD. The investigators anticipate that the successful completion of the project aims will position the eNeighbor as an innovative, stakeholder-centric service that offers robust support for family caregivers of persons with ADRD in the community.",NO,Dementia|Alzheimer Disease,OTHER: Remote activity monitoring system,"Nursing home utilization at 18 months for the person with ADRD, Caregiver report of nursing home use at 18 months., 18-months","Perceptions of change in caregiver self-efficacy, An 8-item survey measure of caregiver self-efficacy. Item responses range from 1 ""very unconfident"" to 5 ""very confident."" Scores are summed and can range from a score of 1 (low self-efficacy) to 40 (high self-efficacy)., Baseline, 6-months, 12-months, 18-months|Perceptions of change in caregiver competence, The 7-item Short Sense of Competence Questionnaire (SSCQ), which assesses individuals' sense of capability in providing assistance to a relative with Alzheimer's disease or related dementias via survey report. Item responses range from 1 = strongly disagree to 5 = strongly agree. Item responses are summed, with a total score range of 5 to 35., Baseline, 6-months, 12-months, 18-months|Perceptions of change in caregiver burden, The 22-item Zarit Burden Interview self-report survey measure. Item responses range from 0 ""never"" to 4 ""nearly always."" Scores are summed and can range from a score of 0 (no burden) to 88 (high burden)., Baseline, 6-months, 12-months, 18-months|Perceptions of change in caregiver role captivity, The 4-item role captivity measure assesses the involuntary aspects of the caregiving role. Item responses range from 1 = ""not at all"" to 4 = ""very much."" The total role captivity score is the sum of item responses with a range of 4 (no role captivity) to 16 (high role captivity)., Baseline, 6-months, 12-months, 18-months|Change in caregiver role overload, The 3-item role overload survey measure ascertains caregivers' feelings of emotional and physical fatigue. Item responses range from 1 = ""not at all"" to 4 = ""very much."" The total role overload score is the sum iof item responses with a range of 4 (no role overload) to 16 (high role overload)., Baseline, 6-months, 12-months, 18-months|Change in frequency/perceptions caregiver depressive symptom severity, The 20-item Center for Epidemiological Studies Depression (CES-D) survey measure is used to assess caregivers' depressive symptoms. Item responses range from 1 = ""Rarely or none of the time (less than 1 day)"" to 5 = ""Most of the time (5-7 days)."" The total CES-D score is summed, with a range of 20 (little to no depressive symptoms) to 100 (frequent depressive symptoms)., Baseline, 6-months, 12-months, 18-months|Perceived acceptability/utility of remote activity monitoring at 6-, 12-, and 18-months, The Remote Activity Monitoring Review Checklist is administered to caregiving participants in the treatment condition at the 6-month, 12-month and 18-month follow-up survey intervals. The checklist consists of 21 self-report survey Likert scale items. Item responses range from 1 = strongly disagree to 5 = strongly agree. The total checklist score is averaged, with a score of 1 = the remote activity monitoring system was not well-received/accepted to 5 = the remote activity monitoring system was very well received/accepted., 6-months, 12-months, 18-months",,University of Minnesota,Agency for Healthcare Research and Quality (AHRQ),ALL,"ADULT, OLDER_ADULT",NA,179,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,1401547541|R18HS022836,2014-04-01,2020-03-31,2020-04-08,2018-09-11,,2023-10-05,,"Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/09/NCT03665909/Prot_SAP_003.pdf"
NCT03033875,"Testing Tele-Savvy, an On-line Psychoeducation Program for Dementia Family Caregivers",https://clinicaltrials.gov/study/NCT03033875,,COMPLETED,"The purpose of this study is to test the psychoeducational program ""Tele-Savvy."" Tele-Savvy is an internet based, group education program developed from an in person program called Savvy Caregiver. Participants will be randomly assigned to either the Tele-Savvy group (receiving only the Tele-Savvy education) or the Healthy Living Education Program (receiving healthy lifestyle education and then Tele-Savvy education 6 months later) or a usual care group (receiving Tele-Savvy education 6 months later). Each program takes 43 days to complete.",YES,Alzheimer Disease|Dementia,BEHAVIORAL: Tele-Savvy|BEHAVIORAL: Healthy Living Education Program,"Zarit Burden Inventory (ZBI) Score, The ZBI is a 22 item scale. Each item on the interview is a statement which the caregiver is asked to endorse using a 5-point scale. Response options range from 0 (Never) to 4 (Nearly Always). Total scores range from 0 (low burden) to 88 (high burden), Baseline, Month 3, Month 6|State-Trait Anxiety Inventory (STAI) State Score, The STAI State (STAI-S) is a 20-item 4-point Likert scale commonly used measure of state anxiety. Respondents report the intensity of their anxiety at that moment on a 4-point scale where 1 = not at all and 4 = very much so. Total scores range from 20 to 80 and higher scores indicate greater anxiety., Baseline, Month 3, Month 6|Center for Epidemiological Studies Depression Scale - Revised (CESD-R) Score, The CESD-R is a 20 item Likert scale scored 0-3 with somatic and psychological subscales. Total scores range from 0 to 60, with high scores indicating greater depressive symptoms., Baseline, Month 3, Month 6","Revised Memory and Behavior Problem Checklist (RMBPC) Reaction Score, The RMBPC is a 24-item instrument that assesses behaviors in persons with dementia and caregiver responses to them. Caregiver reactions to behaviors are scored as 0 = not at all upsetting to 4 = extremely upsetting. Total caregiver reaction scores range from 0 to 96 with higher scores indicating greater feelings of being upset by behaviors of those with dementia that they are providing care for., Baseline, Month 3, Month 6|Pearlin Mastery, Loss, and Competence - Caregiving Competence Subscale Score, The Caregiving Competence Subscale of the Pearlin Mastery, Loss, and Competence instrument has 4 items that are responded to on a 4-point Likert scale where 1 = not at all and 4 = very much. Total scores for this subscale range from 4 to 16 and higher scores indicate greater feelings of competence with caregiving., Baseline, Month 3, Month 6|Pearlin Mastery, Loss, and Competence - Management of Situation Subscale Score, The Management of Situation Subscale of the Pearlin Mastery, Loss, and Competence instrument has 4 items that are responded to on a 4-point Likert scale where 1 = never and 4 = very often. Total scores for this subscale range from 4 to 16 and higher scores indicate greater management of caregiving situations., Baseline, Month 3, Month 6|Perceived Stress Scale (PSS) Score, The PSS is 14-item Likert-type questionnaire. Responses are given on a 5-point scale where 0 = never and 4 = very often. Total scores range from 0 to 56 and certain items are reverse scored so that higher total scores reflect higher perceived stress., Baseline, Month 3, Month 6",,Emory University,National Institute on Aging (NIA),ALL,"ADULT, OLDER_ADULT",NA,261,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,IRB00092812|1R01AG054079-01,2017-05-18,2020-12-04,2020-12-04,2017-01-27,2021-12-03,2022-01-13,"Emory University, Atlanta, Georgia, 30322, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/75/NCT03033875/Prot_SAP_001.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/75/NCT03033875/ICF_000.pdf"
NCT04623242,Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.,https://clinicaltrials.gov/study/NCT04623242,DIAN-TU,COMPLETED,"The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers.

This is an analysis study for an MPRP: DIAN-TU-001 Master NCT01760005",YES,"Alzheimers Disease|Dementia|Alzheimers Disease, Familial",DRUG: Gantenerumab|DRUG: Solanezumab|DRUG: Matching Placebo (Gantenerumab)|DRUG: Matching Placebo (Solanezumab),"Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE);, Multivariate Disease Progression Model adjusted for Estimated Years to Onset (EYO)and includes all timepoints up to treatment discontinuation. The treatment effect is reported relative to the mutation positive placebo arm.

Multivariate Cognitive Endpoint comprising: (i) Wechsler Memory Scale-Revised Logical Memory Delayed Recall Test (MEMUNITS), (ii) Wechsler Adult Intelligence Scale Digit Symbol Substitution Test (WAIS), (iii) Mini-Mental State Examination (MMSE), and (iv) International Shopping List Task (ISLT). Measurements for each test were normalized using the mean (SD) at DIAN-TU-001 baseline for mutation negative subjects. Higher scores indicate more favourable cognitive performance., Baseline through Week 260","Gantenerumab: Rate of Change Over Time- Clinical Dementia Rating Sum of Boxes (CDR-SB), CDR-SB score is considered a more detailed quantitative general index of cognition and function, and provides more information than the global CDR score in patients with mild dementia

Scores range from 0-18 with lower scores showing more favorable cognitive function., Baseline and Weeks 52, 104, 156, 208 and 260|Gantenerumab: Rate of Change Over Time- Functional Assessment Scale (FAS), The Functional Assessment Scale is to be administered and completed by the study partner about subjects for whom they care. This scale measures instrumental activities of daily living such as preparing balanced meals and managing personal finances. The intent of the FAS is to assess change in an individual's functional activities, relative to previously attained abilities, that are caused by cognitive dysfunction. If the study partner indicates that the subject no longer performs a particular task, it is reasonable to probe further and ask if they think the subject could still do the task. This will help tease out the relevant cognitive impairment, Baseline and Weeks 52, 104, 156, 208 and 260|Gantenerumab: Imaging Measures Composite [11C] PiB Partial Volume Corrected Regional Spread Function Standardized Uptake Value Ratio - Composite, In vivo quantification of Î²-amyloid deposition using positron emission tomography. This measure is a composite of brain regions. Higher scores indicate worse disease stage., Baseline, Weeks 52, 104 and 208|Solanezumab: Clinical Measures- Clinical Dementia Rating (CDR), Clinical Dementia Rating - Global Score - Number of Subjects with an Increase from Baseline by Visit, Baseline and Weeks 52, 104, 156, and 208|Solanezumab: Clinical Measures- CDR Sum of Boxes (CDR-SB), CDR-SB score is considered a more detailed quantitative general index and provides more information than the global CDR score in patients with mild dementia

Scores range from 0-18 with lower scores showing more favorable cognitive function., Baseline and Weeks 52, 104, 156, and 208|Solanezumab: Clinical Measures- Geriatric Depression Scale (GDS), The Geriatric Depression Scale (GDS) is a self-report measure of depression in older adults. Users respond in a ""Yes/No"" format. Of the 15 items, 10 indicate the presence of depression when answered positively while the other 5 are indicative of depression when answered negatively.

Scores range from 0-15 for completed questionnaires. A score of 88 is recorded for participants unable to complete the test.

Lower scores show more favorable outcome., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Clinical Measures- Neuropsychiatric Inventory Questionnaire (NPI-Q), The questionnaire is to be administered and completed by the study partner about patients for whom they care. Each of the 12 NPI-Q domains contains a survey question that reflects cardinal symptoms of that domain. Initial responses to each domain question are ""Yes""(present) or ""No"" (absent). If the response to the domain question is ""No"", the study partner goes to the next question. If ""Yes"", the study partner then rates both the Severity of the symptoms present within the last month on a 3-point scale and the associated impact of the symptom manifestations on them (i.e. Caregiver Distress) using a 5-point scale. The NPI-Q provides symptom 'Severity' and 'Distress' ratings for each symptom reported, and total 'Severity' and 'Distress' scores reflecting the sum of individual domain scores.

Scores range from 0-36 with lower scores indicating more favorable cognitive function., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Clinical Measures- Functional Assessment Scale (FAS), The Functional Assessment Scale is to be administered and completed by the study partner about subjects for whom they care. This scale measures instrumental activities of daily living such as preparing balanced meals and managing personal finances. The intent of the FAS is to assess change in an individual's functional activities, relative to previously attained abilities, that are caused by cognitive dysfunction. If the study partner indicates that the subject no longer performs a particular task, it is reasonable to probe further and ask if they think the subject could still do the task. This will help tease out the relevant cognitive impairment

Scores range from 0-30 with lower scores indicate more favorable cognitive performance, Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Clinical Measures- Mini-Mental Status State Examination (MMSE), MMSE is a brief, quantitative measure of cognitive status in adults used to screen for cognitive impairment, to estimate the severity of cognitive impairment at a given point in time, to follow the course of cognitive changes in an individual over time, and to document an individual's response to treatment.

Scores range from 0-30 and higher scores indicate more favorable cognitive function., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- International Shopping List Task 30-Minute Delayed Recall, Classic list-learning test that measures verbal learning \& memory.

Scores range from 0-12 with higher scores indicating more favorable cognitive performance., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- Groton Maze Learning Test 30 Minute Delayed Recall, The Groton Maze Learning Test 30 minute delayed recall measures episodic memory. The primary outcome is the number of errors made during recall of the previously memorized pathway from the Groton Maze Learning Test. The minimum score is 0 errors and the max is 999. Lower scores indicate better cognitive performance., Baseline, Week 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- Groton Maze Learning Test Delayed Reversed Recall, The Groton Maze Learning Test measures executive function using a maze learning paradigm. A 10 x 10 grid of tiles is presented to the participant on the screen. A 28-step pathway is hidden among these tiles. A blue tile indicates the start and a tile with red circles indicates the finish. The participant must move one step at a time from the start toward the end by touching a tile next to their current location. If the correct move is made a green checkmark appears and if the move is incorrect a red cross is revealed. Once completed, they are returned to the start location to repeat the test and must try to remember the pathway they have just completed. ""Delayed Reverse Recall"" measures spatial working memory.

The outcome is the number of errors made with the range of 0-999. Lower scores indicate better cognitive performance., Baseline, Week 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- Trailmaking Test Part A, Trail Making test taps attention, processing speed, and executive function. Part A consists of 25 circles numbered 1 through 25 distributed over a white sheet of standard document-sized paper. The subject is instructed to connect the circles with a drawn line as quickly as possible in ascending numerical order without lifting their pen.

The subject's performance is judged in terms of the time, in seconds, required to complete each trail (Max time 150 seconds). Lower scores indicate more favorable cognitive function., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- Trailmaking Test Part B, This test taps attention, processing speed, and executive function and depends on visuo-motor and perceptual-scanning skills and also requires considerable cognitive flexibility in shifting from number to letter sets under time pressure. Part B consists of 25 circles, but these circles contain either numbers (1 through 13) or letters (A through L). The subject must connect the circles while alternating between numbers and letters in an ascending order (e.g., A to 1; 1 to B; B to 2; 2 to C).

The subject's performance is judged in terms of the time, in seconds, required to complete each Trail (Max of 300 seconds). Lower scores indicate more favorable cognitive function., Baseline, Weeks 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- WAIS-R Digit-Symbol Substitution Test, This test engages multiple cognitive abilities, including attention, psychomotor speed, complex scanning, visual tracking, and immediate memory.

Scores range from 0-93 with higher scores indicate more favorable cognitive function., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- WMS-R Digit Span Backward, Widely used measure of working memory (or attention) in which the subject is read number sequences of increasing length and then asked to repeat each sequence backward. The primary measure of performance is the number of digit sequences correctly reversed.

The unit of measure is number of digit sequences correctly recalled and ranges from 0-12. Higher scores indicate more favorable cognitive function., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- WMS-R Digit Span Forward, This is a widely-used test of working memory in which the subject is read number sequences of increasing length and asked to repeat them. The total score is the number of sequences correctly repeated.

The unit of measure is number of digit sequences correctly recalled and ranges from 0-12. Higher scores indicate more favorable cognitive function., Baseline, Weeks 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- Raven's Progressive Matrices (Set A), This is a measure of fluid intelligence. This test is used to get an estimate of the subjects IQ at baseline. Subjects are asked to complete a visual pattern by circling one of six response choices.

Scores range from 0-12 with higher scores indicating more favorable cognitive performance., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- Category Fluency (Animals), Category Fluency is a widely used measure of semantic memory (verbal fluency, language). The subject is asked to name different exemplars of a given semantic category (animals), and the number of unique exemplars named is scored.

Higher scores indicate more favorable cognitive function., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- Category Fluency (Vegetables), Category Fluency is a widely used measure of semantic memory (verbal fluency, language). The subject is asked to name different exemplars of a given semantic category (vegetables), and the number of unique exemplars named is scored.

Higher scores indicate more favorable cognitive function., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- WMS-R Logical Memory Delayed Recall Test, Measure of delayed recall (episodic memory) of a story read to the subject at the beginning of the testing session and subject is asked to relay the story 20 minutes later.

Scores range from 0-25 with higher scores indicating more favorable cognitive performance., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- WMS-R Logical Memory Immediate Recall Test, This test assesses the ability to recall a short story. The subject is read a short story and immediately after hearing the story, the subject is asked to retell the story from memory.

Scores range from 0-25 with higher scores indicating more favorable cognitive performance., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Cognitive Measures- Composite Including: Alternative Multivariate Composite: (1) Digit Span Backwards; (2) Logical Memory (Immediate); (3) Trailmaking B; (4) Category Fluency (Animals), Multivariate Disease Progression Model adjusted for estimated years from symptom onset (EYO) and includes all time points up to treatment discontinuation. The treatment effect for Solanezumab is reported relative to the mutation positive placebo arm.

This alternative multivariate endpoint includes four tests: Logical Memory Immediate Recall, Digit Span Backward Recall, Category Fluency (Animals), Trailmaking Test Part B. Measurements for each test will be normalized using the mean (SD) at DIAN-TU-001 baseline among mutation negative subjects before being analyzed. For the Trailmaking Test B, the scores will be multiplied by -1 as higher scores indicate worse performance; whereas for the other three, lower scores indicate worse performance. Therefore, on the standardized endpoints, lower scores indicate worse performance., Baseline through Week 260|Solanezumab: Imaging Measures- Brain Amyloid Load as Measured by [11C]PiB-PET Non-partial Volume Corrected, PiB Standardized Uptake Value Ratio (\[11C\]PiB SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions dervived via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD., Baseline and Weeks 52, 104 and 208|Solanezumab: Imaging Measures- Brain Amyloid Load as Measured by Florbetapir PET, Florbetapir Standardized Uptake Value Ratio (\[18F\]AV-45 SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions derivved via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD., Weeks104 and 208|Solanezumab: Imaging Measures- Brain Glucose Metabolism as Measured by Fluorodeoxyglucose (FDG)-PET Non-partial Volume Corrected, FDG Standardized Uptake Value Ratio (\[18F\]FDG SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions derivved via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD., Baseline and Weeks 52, 104 and 208|Solanezumab: Imaging Measures- Brain Atrophy as Measured by Cortical Thickness of Regions of Interest - Precuneus Region, Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. For the clinical trial we examined cortical thickness values in prespecified regions of interest known to show atrophy in autosomal dominant Alzheimer Disease. Higher measurements are more favorable., Baseline and Weeks 52, 104, 156 and 208|Solanezumab: Imaging Measures- Volumetric MRI Combined Total Volume Corrected for Head Size - Hippocampus Volume, Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. For the clinical trial we examined volume values in prespecified regions of interest known to show atrophy in autosomal dominant Alzheimer Disease., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Imaging Measures- Brain Tau Load as Measured by Flortaucipir PET Non-partial Volume Corrected, This variable represents how much neurofibrillary tau pathology is present in brain as assessed using positron emission tomography (PET). Scans were conducted using \[F18\] Flortaucipir, a commonly used tracer in the field., Baseline and Weeks 52, 104 and 208|Solanezumab: Imaging Measures- Brain Atrophy as Measured by Whole Brain Volume Corrected for Head Size, Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. A whole brain volume measure was generated to represent global atrophy across the cortical and subcortical regions., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Imaging Measures- Brain Atrophy as Measured by Ventricular Volume (Volumetric MRI) Corrected for Head Size, Rather than looking at how tissue in the brain changes, it is also possible to quantify how the ventricles, fluid filled spaces in the brain, change. Increasing ventricular volume represents greater amounts of cerebral spinal fluid which suggests atrophy of the brain. Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequences were processed using the Freesurfer software suite. Total ventricular volume was calculated from the ventricular volumes generated by this program., Baseline and Weeks 52, 104, 156, 208 and 260|Solanezumab: Fluid Biomarker Measures- CSF AÎ² 40 Free Change From Baseline, Measured concentration of the drug bound and free soluble AÎ²1-40 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA), Baseline and Weeks 52, 104 and 208|Solanezumab: Fluid Biomarker Measures- CSF AÎ² 42 Free, Measured concentration of the total soluble AÎ² 1-42 peptide in cerebrospinal fluid using ELISA, Baseline and Weeks 52, 104 and 208|Solanezumab: Fluid Biomarker Measures- CSF Tau, Measured concentration of the soluble Tau peptide in cerebrospinal fluid, Baseline and Weeks 52, 104 and 208|Solanezumab: Fluid Biomarker Measures- CSF pTau 181, Measured concentration of phosphorylated tau at threonine-181 in cerebrospinal fluid, Baseline and Weeks 52, 104 and 208|Solanezumab: Change From Baseline Fluid Biomarker Measures- CSF Neurofilament Light Chain (NfL), Measured concentration of neurofilament light chain in cerebrospinal fluid using SIMO, Baseline and Weeks 52, 104 and 208|Solanezumab: Fluid Biomarker Measures- Plasma Neurofilament Light Chain (NfL), Measured concentration of neurofilamnet light chain in plasma using Single Molecule Array (SIMOA), Baseline and Weeks 52, 104 and 208|Solanezumab: Fluid Biomarker Measures- Plasma Anti-drug Antibodies (ADA), Measurement of the presence or absence of anti-drug antibodies in serum

Note: Mutation Negative Placebo subjects are not displayed as anti-drug antibody testing was not to be evaluated for these subjects.

Note: Treatment Emergent Anti-Drug Antibody Positive subjects are defined as those with either (a) a baseline status of ADA Not Present and at least one post-baseline ADA present with a titer \>= 1:20 or (b) both a baseline and post-baseline status of ADA Present with the post-baseline titer being 2 dilutions (4-fold) greater than the baseline titer.

Note: Treatment Emergent Anti-Drug Antibody Inconclusive subjects are defined as those for whom \>=20% of the subject's post-baseline ADA results are ADA Inconclusive and all remaining post-baseline samples are ADA Not Present.

Note: Treatment Emergent Anti-Drug Antibody Negative subjects are defined as those who are evaluable for TE ADA but are neither TE ADA Positive nor TE ADA Inconclusive., Baseline and Weeks 52, 104 and 208|Solanezumab: Fluid Biomarker Measures- Total Plasma AÎ² 1-40, Measured concentration of the total soluble AÎ² 1-40 peptide in cerebrospinal fluid using ELISA, Baseline and Weeks 52, 104 and 208|Solanezumab: Fluid Biomarker Measures- Total Plasma AÎ² 42, Measured concentration of the total soluble AÎ² 1-42 peptide in cerebrospinal fluid using ELISA, Baseline and Weeks 52, 104 and 208|Solanezumab: Fluid Biomarker Measures- CSF AÎ² 42 Total, Measured concentration of the total soluble AÎ²1-42 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA), Baseline and Weeks 52, 104 and 208|Solanezumab: Fluid Biomarker Measures- CSF AÎ² 40 Total, Measured concentration of the total soluble AÎ²1-40 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA), Baseline and Weeks 52, 104 and 208",,Washington University School of Medicine,Eli Lilly and Company|Hoffmann-La Roche|Alzheimer's Association|National Institute on Aging (NIA)|Avid Radiopharmaceuticals|Accelerating Medicines Partnership (AMP),ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,194,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",DIAN-TU-001 (gant-sola)|The Alzheimer's Association|U01AG042791|2013-000307-17|R01AG046179|REec-2014-0817|The Alzheimer's Association|GHR Foundation|Alzheimer's Association,2012-12,2019-11-22,2020-03-06,2020-11-10,2021-02-27,2022-09-22,"University of Alabama in Birmingham, Birmingham, Alabama, 35294, United States|University of California San Diego Medical Center, La Jolla, California, 92037, United States|Yale University School of Medicine, New Haven, Connecticut, 06510, United States|Emory University, Atlanta, Georgia, 30329, United States|Indiana University School of Medicine, Indianapolis, Indiana, 46202, United States|Washington University in St. Louis, Saint Louis, Missouri, 63110, United States|Columbia University, New York, New York, 10032, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States|Butler Hospital, Providence, Rhode Island, 02096, United States|University of Washington, Seattle, Washington, 98195, United States|Neuroscience Research Australia, Randwick, New South Wales, 2031, Australia|Mental Health Research Institute, Melbourne, Victoria, 3010, Australia|The McCuster Foundation of Alzheimer's Disease Research, Nedlands, Western Australia, 6009, Australia|UBC Hospital, Vancouver, British Columbia, V6T 2B5, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|McGill Center for Studies in Aging, Verdun, Quebec, H4H 1R3, Canada|CHU de Toulouse - HÃ´pital Purpan, Toulouse, Haute Garonne, 31059, France|Hopital Roger Salengro - CHU Lille, Lille, Nord, 59037, France|Groupe Hospitalier Pitie-Salpetriere, Paris cedex 13, Paris, 69677, France|Hopital Neurologique Pierre Wertheimer, Bron cedex, Rhone, 69677, France|CHU de Rouen - HÃ´pital Charles Nicolle, Rouen, Seine Maritime, 76031, France|St Vincent's University Hospital, Dublin, DUBLIN 4, Ireland|University of Puerto Rico, School of Medicine, San Juan, 00936, Puerto Rico|Hospital ClÃ­nic I Provincial de Barcelona, Barcelona, 8036, Spain|The National Hospital for Neurology and Neurosurgery, London, Greater London, WC1B 3BG, United Kingdom","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/42/NCT04623242/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/42/NCT04623242/SAP_001.pdf"
NCT06038643,Intergenerational Behavioral Intervention to Enhance Physical Activity in Older Adults at Risk for Alzheimer's Disease,https://clinicaltrials.gov/study/NCT06038643,HABS,RECRUITING,"This is a twelve-week pilot randomized controlled trial of a behavioral intervention in older adults at risk for Alzheimer's disease. Older participants are a subgroup from the PREVENT-AD longitudinal cohort. We will test whether a four-week intergenerational social motivation using a technology-based platform (intervention group) enhances physical activity relative to a control group. After a washout period, the two groups will be offered the opportunity to cross-over into the alternate condition.",NO,Physical Inactivity,BEHAVIORAL: Motivational behavioural intervention and daily activities monitoring|BEHAVIORAL: Active Control,"Sedentary behavior (average min/day), This metric quantifies the change in the average amount of time spent sedentary each day, from the baseline period to the 4-week period. It is a marker of time spent inactive., Baseline; 4-week|Total step count (average steps/day), This metric quantifies the change in the average number of steps taken each day, from the baseline period to the 4-week period. It is a marker of change in habitual ambulatory activity., Baseline; 4-week","Moderate-vigorous activity (average min/day), This metric quantifies the change in the average amount of time spent engaged in moderate-vigorous physical activity each day, from the baseline period to the 4-week followup period. It is a marker of physical activity., Baseline; 4-week|UCLA Loneliness Scale, A questionnaire that measures perceived level of loneliness., Baseline; 4-week|Pittsburgh Sleep Quality Index, A questionnaire measuring sleep quality., Baseline; 4-week|Modified Differential Emotions Scale, A questionnaire that assesses mood and feelings., Baseline; 4-week|Test My Brain Digital Neuropsychology Toolkit, This metric assessed cognitive status across multiple domains (e.g., memory, executive function, processing speed), Baseline; 4-week|Barriers to Self-Efficacy Scale, A questionnaire to assess physical activity confidence when faced with challenges (e.g., bad weather)., Baseline; 4-week|Perceived Stress Scale (PSS), This common test assesses the perception of stress., Baseline; 4-week",,Douglas Mental Health University Institute,Montreal Neurological Institute and Hospital|McGill University|National Institute on Aging (NIA),ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",IUSMD-20-38|P30AG048785,2023-10-24,2024-02-20,2024-05-30,2023-09-15,,2023-10-31,"Douglas Mental Health University Institute, MontrÃ©al, Quebec, H4H 1R3, Canada","Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/43/NCT06038643/SAP_000.pdf"
NCT04009629,Dementia Risk and Dynamic Response to Exercise,https://clinicaltrials.gov/study/NCT04009629,DYNAMIC,COMPLETED,"Research suggests that physical exercise supports brain health and cognition as we age. The goal of this project is to examine the specific changes in brain blood flow and biological factors in the blood immediately after exercise in older adults who have the APOE4 gene, a genetic risk factor for developing Alzheimer's. Results from this study will help researchers and clinicians understand and measure changes in the body and brain as a function of exercise, and how those changes relate to Alzheimer's risk.",YES,Alzheimer Disease 2 Due to Apoe4 Isoform|Healthy Aging,BEHAVIORAL: Moderate Intensity Aerobic Exercise,"Cerebral Blood Flow Area Under Curve, Cumulative cerebral blood flow measured by Arterial Spin Labeling MRI. The standard arterial spin labeling unit of measure is average milliliters per 100 grams of tissue per minute (mL/100g tissue/minute). For the present analysis, we summed perfusion over the entire acquisition period, 23.2 minutes, rather than averaging. Therefore the units are milliliters per 100 grams of tissue, ~24 minutes","Insulin-like Growth Factor-1 Change, Change in circulating Insulin-like Growth Factor-1 from pre-to-post exercise, Pre-to-post intervention (~15 minutes)|Vascular Endothelial Growth Factor Change, Change in circulating Vascular Endothelial Growth Factor from pre-to-post exercise, Pre-to-post intervention (~15 minutes)|Brain Derived Neurotrophic Factor Change, Change in circulating Brain Derived Neurotrophic Factor from pre-to-post exercise, Pre-to-post intervention (~15 minutes)",,University of Kansas Medical Center,National Institute on Aging (NIA),ALL,OLDER_ADULT,NA,61,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,STUDY00142822|R21AG061548,2019-10-25,2021-10-28,2021-10-28,2019-07-05,2022-02-09,2022-05-03,"University of Kansas Alzheimer's Disease Center, Fairway, Kansas, 66205, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/29/NCT04009629/Prot_SAP_000.pdf"
NCT02016560,"Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects",https://clinicaltrials.gov/study/NCT02016560,MCI,COMPLETED,A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).,YES,Alzheimer's Disease,DRUG: florbetapir F 18|DRUG: Flortaucipir F18|PROCEDURE: Brain PET Scan,"Confirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline, Confirm the relationship between neocortical flortaucipir uptake and the subsequent rate of cognitive decline at longitudinal follow up that was observed in the Exploratory Phase of the study. Patients were assigned to groups by majority classification of the flortaucipir positron emission tomography (PET) scan by five independent imaging physicians. Clinically meaningful cognitive and functional deterioration was defined as a 1 point or greater worsening on clinical dementia rating - sum of boxes (CDR-SB) score over the follow-up period., between baseline and 18 months|Exploratory Phase: Cross-sectional Flortaucipir Imaging Results, Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain., baseline scan|Exploratory Phase: Longitudinal Change in Tau Deposition Over Time, by Amyloid Status, Assess the rate of change of tau deposition as measured by flortaucipir uptake (SUVr) over time. Change = 18 months SUVr - baseline SUVr., baseline and 18 months","Confirmatory Phase: Diagnostic Performance of Flortaucipir Visual Read, This analysis used dichotomized CDR-SB change as a truth standard (1 point or more worsening = true positive vs. less than 1 point worsening = true negative) to assess the diagnostic performance of baseline Advanced AD tau status (Ï„AD++) as determined by flortaucipir scan interpretation. Sensitivity and Specificity were calculated for each of the 5 independent imaging readers. Sensitivity is the percentage of true positive cases correctly identified by an Advanced AD pattern scan. Specificity is the percentage of true negative cases correctly identified by scans that were not classified as Advanced AD pattern., baseline and 18 months|Exploratory Phase: Correlation Between Flortaucipir SUVr and Age, Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain., baseline scan",,Avid Radiopharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,383,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC,18F-AV-1451-A05,2013-12,2017-07-28,2017-07-28,2013-12-20,2020-06-27,2020-09-22,"Banner Alzheimer's Institute, Phoenix, Arizona, 85006, United States|Four Peaks Neurology, Scottsdale, Arizona, 85258, United States|Mayo Clinic, Scottsdale, Arizona, 85259, United States|Banner Sun Health Research Institute, Sun City, Arizona, 85351, United States|UC Irvine, Irvine, California, 92697, United States|Hoag Memorial, Newport Beach, California, 92663, United States|Norther California PET Imaging Center, Sacramento, California, 95816, United States|UC Davis, Sacramento, California, 95817, United States|UC San Francisco, San Francisco, California, 94158, United States|Neurological Research Institute, Santa Monica, California, 90404, United States|Molecular NeuroImaging, New Haven, Connecticut, 06510, United States|Quantum Laboratories, Deerfield Beach, Florida, 33064, United States|21st Century Oncology, Fort Myers, Florida, 33912, United States|Sandlake Imaging, Orlando, Florida, 32806, United States|Meridien Research, Saint Petersburg, Florida, 33709, United States|USF Health Byrd Alzheimer's Center, Tampa, Florida, 33613, United States|Independent Imaging, West Palm Beach, Florida, 33407, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Boston University, Boston, Massachusetts, 02118, United States|Alzheimer's Disease Center, Quincy, Massachusetts, 02169, United States|Center for Clinical Imaging Research, Saint Louis, Missouri, 63110, United States|Las Vegas Radiology, Las Vegas, Nevada, 89147, United States|Center for Brain Health - NYU Langone Medical Center, New York, New York, 10016, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Rhode Island Hospital, Providence, Rhode Island, 02903, United States|Butler Hospital, Providence, Rhode Island, 02906, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/60/NCT02016560/Prot_000.pdf|Statistical Analysis Plan: Confirmatory Phase SAP, https://storage.googleapis.com/ctgov2-large-docs/60/NCT02016560/SAP_001.pdf|Statistical Analysis Plan: Confirmatory Phase Addendum SAP, https://storage.googleapis.com/ctgov2-large-docs/60/NCT02016560/SAP_002.pdf|Statistical Analysis Plan: Exploratory Phase SAP, https://storage.googleapis.com/ctgov2-large-docs/60/NCT02016560/SAP_003.pdf"
NCT04058886,Telephone-delivered Mindfulness Intervention for African American Dementia Caregivers,https://clinicaltrials.gov/study/NCT04058886,,COMPLETED,"This study is assesses the feasibility and acceptability of telephone-delivered mindfulness training designed to alleviate caregiver burden for African-American rural caregivers of individuals with moderate to severe dementia, as defined by the caregiver. The study utilizes a single-group, uncontrolled design to test the feasibility and acceptability of the intervention for the target population.",YES,Alzheimer Dementia|Caregiver|Dementia Alzheimers,BEHAVIORAL: Telephone-delivered Mindfulness,"Number of Participants Attending at Least 6 Telephone Sessions, The instructor will conduct a role call to take attendance at the beginning of each of the 8 class sessions and 1 retreat session. Eighty-five percent of participants who start the intervention will complete at least 6 out of 9 intervention sessions. Attendance used as a proxy to assess intervention acceptability., 8 weeks|Percent of Dyads Who Endorse the Program, The intervention will be acceptable to informal caregiving teams as evidenced by an 85 percent (95% Confidence Interval (CI): 72.5, 97.5) endorsement of the program in post-participation interviews. Calculated based on responses to open-ended questions regarding participants' experiences of the intervention. Examples of questions are: ""how valuable or beneficial was the mindfulness training to you?"" and ""what challenges did you have with the training?"" and ""what did you expect from the training that you did not get?"". Endorsement was considered positive if the expressions of value outweighed challenges (i.e., positive comments outweighed negative comments by dyad). Data reported as caregiving teams (dyads) in accordance with the protocol., 8 weeks","Change From Baseline in the Zarit Burden Interview Short Form (ZBI-12) Score, The ZBI-12 is a 12-item (SF) version of the original 29-item questionnaire measures role strain and personal strain. Items are measured on a 5-point Likert scale (0=never to 4=nearly always). Scores range from 0-48 with lower scores representing less burden. Within group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline in the Family Satisfaction Scale (FSS) Score, The FSS is a 10-item scale which uses a 5-point Likert scale (1=very dissatisfied to 5=extremely satisfied). Total scores range from 10-50 with higher scores representing more endorsement of family satisfaction. The FSS was administered at Baseline and Week 8. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., up to 8 weeks|Change From Baseline in Intolerance of Uncertainty Scale (IUS-12) Prospective Subscale Score, The prospective anxiety subscale of the Intolerance of Uncertainty Scale (IUS-12) is a 7-item measure. The measure uses a 5-point Likert scale (1=not at all like me to 5=entirely like me). Scores range from 7-35, with lower scores reflecting more tolerance of uncertain situations. IUS-12 was administered at Baseline and at 8 weeks. Change scores are reported from paired t-tests for within-group assessments and from mixed effects models for the total population controlling for caregiving role, severity of dementia in the care recipient and dependencies in the data (individuals within families within cohorts)., up to 8 weeks|Change From Baseline in Intolerance of Uncertainty Scale (IUS-12) Inhibitory Subscale Score, The inhibitory subscale of the Intolerance of Uncertainty Scale (IUS-12) is a 5-item measure. The measure uses a 5-point Likert scale (1=not at all like me to 5=entirely like me). Total scores range from 5-25, with lower scores reflecting more tolerance of uncertain situations. IUS-12 was administered at baseline and at 8 weeks. Within group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., up to 8 weeks|Change From Baseline on PROMIS Meaning and Purpose-Short Form 6a, The Patient-Reported Outcomes Measurement Information System (PROMIS) Meaning and Purpose-Short Form 6a is a 6-item scale that assesses a sense that life has purpose and there are good reasons for living, including hopefulness, optimism, goal-directedness, and feelings that one's life is worthy. It uses a 5-point Likert scale (1=strongly disagree to 5=strongly agree). Raw scores range from 6-30 with higher scores representing more endorsement of meaning and life. Raw scores are converted to T-scores based on population norms with a mean of 50 and standard deviation of 10. Therefore a score of 60 represents 1 standard deviation above the population average and indicates a high level of meaning and purpose. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on Cognitive and Affective Mindfulness Scale-Revised (CAMS-R), The CAMS-R is a 12-item scale measuring mindfulness by using language that is not representative of any particular meditation training or practice. It uses a 4-point Likert scale with responses ranging from 1 (Rarely/Not at all) to 4 (Almost always). Total scores range from 12-48. Higher scores indicate higher levels of mindfulness. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on PROMIS Emotional Distress-Anxiety-Short Form 4a, The Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional Distress-Anxiety-Short Form 4a is a 4-item scale that assesses fear (fearfulness, panic), anxious misery (worry, dread), hyperarousal (tension, nervousness, restlessness), and somatic symptoms related to arousal (racing heart, dizziness). It uses a 5-point Likert scale (1=never to 5=always). Raw scores range from 4-20 and are standardized to T-scores based on population averages (mean 50 and standard deviation 10). A score less than 55 is within normal limits. A score between 55-59.9 represents mild anxiety. A score greater than 60-69.9 represents moderate anxiety and a score of 70 or greater represents severe anxiety. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on PROMIS Emotional Distress-Anger-Short Form 5a, The Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional Distress-Anger-Short Form 5a item is a 5-item scale that assesses angry mood (irritability, frustration), negative social cognitions (interpersonal sensitivity, envy, disagreeableness), and efforts to control anger. It uses a 5-point Likert scale (1=never to 5=always). Raw scores range from 5-25 and are standardized to T-scores based on population averages (mean 50 and standard deviation 10). A score less than 55 is within normal limits. A score between 55-59.9 represents mild anger; 60-69.9 represents moderate anger and 70 or greater represents severe anger. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on PROMIS Global Physical Health, The Patient-Reported Outcomes Measurement Information System (PROMIS) Global Physical Health is a 2-item scale that assesses overall evaluation of one's physical health. It is based on the well-validated Rand measure, assessing general self-rated physical health, physical function, pain, and fatigue. It uses a 5-point Likert scale (1=poor to 5=excellent). Raw scores range from 2-10 and are standardized to T-scores with a population average of 50 and standard deviation of 10. Suggested cut points include 58 or higher = excellent; 50-57.9 = very good; 42-49.9 = good; 35-41.9 = fair, and less than 35 = poor. Change scores are reported from mixed effects models that utilize the entire population., Baseline, 8 weeks|Change From Baseline on Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form, Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form is an 18-item measure consisting of 5 positive coping strategies (acceptance, positive refocusing, planning, positive reappraisal, putting into perspective) and 4 negative strategies (rumination, catastrophizing, self-blame, other-blame). Total scores range from 18-90 with higher scores representing more cognitive emotional regulation. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving roles, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form (Acceptance), Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form acceptance subscale consisting of two questions. The subscale scores range from 2-10 with higher scores representing greater acceptance coping. Change scores are reported from mixed effects models controlling for caregiving role, severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form (Positive Refocusing), Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form positive refocusing subscale consisting of two questions. The subscale scores range from 2-10 with higher scores representing greater positive refocusing coping strategy. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving roles, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form (Planning), Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form planning subscale consisting of two questions. The subscale scores range from 2-10 with higher scores representing greater planning. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving roles, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form (Positive Reappraisal), Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form positive reappraisal subscale consisting of two questions. The subscale scores range from 2-10 with higher scores representing greater positive reappraisal. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving roles, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form (Putting Into Perspective), Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form putting into perspective subscale consisting of two questions. The subscale scores range from 2-10 with higher scores representing greater putting into perspective coping strategy. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving roles, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form (Rumination), Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form rumination subscale consisting of two questions. The subscale scores range from 2-10 with higher scores representing greater rumination. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form (Catastrophizing), Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form catastrophizing subscale consisting of two questions. The subscale scores range from 2-10 with higher scores representing greater catastrophizing coping. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form (Self-Blame), Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form self-blame subscale consisting of two questions. The subscale scores range from 2-10 with higher scores representing greater self-blame as a coping strategy. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving roles, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form (Other-Blame), Cognitive Emotional Regulation Questionnaire (CERQ)-Short Form other-blame subscale consisting of two questions. The subscale scores range from 2-10 with higher scores representing greater blaming others as a coping strategy. Change scores are reported from mixed effects models controlling for caregiving role, severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on PROMIS Emotional Support-Short Form 4a, The Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional Support-Short Form 4a is a 4-item scale that assesses perceived feelings of being cared for and valued as a person and having confidant relationships. Item responses use a 5-point LIkert scale (1=never to 5=always). Raw scores range from 4-20. The PROMIS Emotional Support item is reported as a T score standardized to a population mean of 50 and standard deviation of 10 with higher scores reflecting more positive endorsement of emotional support. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on PROMIS Informational Support-Short Form 4a, The Patient-Reported Outcomes Measurement Information System (PROMIS) Informational Support-Short Form 4a is a 4-item scale that assesses perceived availability of helpful information or advice. Item responses use a 5-point LIkert scale (1=never to 5=always). Raw scores range from 4-20. The PROMIS Informational Support item is reported as a T score standardized to a population mean of 50 and standard deviation of 10 with higher scores reflecting more positive endorsement of informational support. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on PROMIS Instrumental Support-Short Form 4a, The PROMIS Instrumental Support-Short Form 4a is a 4-item scale that assesses perceived availability of assistance with material, cognitive or task performance. Item responses use a 5-point LIkert scale (1=never to 5=always). Raw scores range from 4-20. The PROMIS Instrumental Support item is reported as a T score standardized to a population mean of 50 and standard deviation of 10 with higher scores reflecting more positive endorsement of instrumental support. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on PROMIS General Self-Efficacy-Short Form 4a, The Patient-Reported Outcomes Measurement Information System (PROMIS) General Self-Efficacy-Short Form 4a is a 4-item scale that assesses confidence in ability to successfully perform specific tasks or behaviors related to one's health in a variety of situations. Items are measured on a 5-point Likert scale (1=I am not at all confident to 5=I am very confident). Raw scores range from 4-20. The PROMIS General Self-Efficacy item is reported as a T score standardized to a population mean of 50 and standard deviation of 10 with higher scores reflecting more positive endorsement of self-efficacy. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline in Mean NPI-Q Distress Scores, The Neuropsychiatric Inventory (NPI-Q) Caregiver Distress subscale uses a 6-point scale with 12 items and scores ranging from 0-60. The NPI-Q measures the degree of distress associated with symptoms associated with dementia e.g., delusions, appetite change, and anxiety. Higher scores indicate more distress. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on PROMIS Self-Efficacy for Managing Emotions-Short Form 4a, The Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy for Managing Emotions-Short Form 4a is a 4-item scale that assesses confidence to manage/control symptoms of anxiety, depression, helplessness, discouragement, frustration, disappointment and anger. Items are measured using a 5-point Likert scale (1=I am not at all confident to 5=I am very confident). Raw scores range from 4-20. The PROMIS Self-Efficacy for Managing Emotions item is reported as a T score standardized to a population mean of 50 and standard deviation of 10 with higher scores reflecting more positive endorsement of managing emotion. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline in the Family Conflict Strategies for Care Subscale, The FCS is a 12-item scale that measures the degree of conflict the family experiences about the seriousness of the care recipient's condition, concerns about the care recipient's safety, what the care recipient can do for him/herself, and whether a nursing home is indicated. The first subscale measures conflict around definitions of the illness and strategies for care (4 items). Items are measured on a 4-point Likert scale (1=no disagreement to 4=quite a bit of disagreement). The total scores range from 4-16 with lower scores representing less family conflict. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline in the Family Conflict Scale Attitudes and Actions Toward the Patient Subscale, The FCS is a 12-item scale that measures the degree of conflict the family experiences about the seriousness of the care recipient's condition, concerns about the care recipient's safety, what the care recipient can do for him/herself, and whether a nursing home is indicated. The second subscale measures conflict around family members' attitudes and action toward the patient (4 items) Items are measured on a 4-point Likert scale (1=no disagreement to 4=quite a bit of disagreement). The total scores range from 4-16 with lower scores representing less family conflict. Within-group change scores are reported based on paired t-tests. Total change scores are reported from mixed effects models controlling for caregiving role, the severity of dementia in the care recipient, and dependencies in the data (individuals within families within cohorts)., Baseline, 8 weeks|Change From Baseline on Family Conflict Scale (FCS) Actions and Attitudes Toward the Caregiver Subscale, The FCS is a 12-item scale that measures the degree of conflict the family experiences about the seriousness of the care recipient's condition, concerns about the care recipient's safety, what the care recipient can do for him/herself, and whether a nursing home is indicated. The third subscale measures conflict around family members' actions and attitudes around the caregiver (4 items). Items are measured on a 4-point Likert scale (1=no disagreement to 4=quite a bit of disagreement). The total scores range from 4-16 with lower scores representing less family conflict. This measure was requested from the primary caregiver only. Change scores are reported from mixed effects models controlling for the severity of dementia in the care recipient and dependencies in the data (individuals within cohorts)., Baseline, 8 weeks",,"University of North Carolina, Chapel Hill",National Institute on Aging (NIA),ALL,"ADULT, OLDER_ADULT",NA,57,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,19-0053|R21AG061728,2019-11-15,2022-07-04,2022-07-06,2019-08-16,2023-05-15,2023-07-19,"UNC Program on Integrative Medicine, Chapel Hill, North Carolina, 27599-7200, United States","Study Protocol, Statistical Analysis Plan, and Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/86/NCT04058886/Prot_SAP_ICF_000.pdf"
NCT03360019,Accurate WiFi-Based Localization of Dementia Patients For Caregiver Support:,https://clinicaltrials.gov/study/NCT03360019,,COMPLETED,"In this Phase II SBIR project we will enhance a wireless WiFi-based insole that was designed and successfully tested during a Phase I trial with elderly persons with dementia and their caregivers, and then investigate its efficacy in terms of caregiver activity, burden, and quality of life in Phase II. Evaluation will use semi-structured interviews and participant observation data collected from professional and family caregivers of patients with moderate or mild dementia.",YES,"Dementia, Vascular|Alzheimer Dementia|Lewy Body Dementia With Behavioral Disturbance",DEVICE: Activlink insole|OTHER: Activlink Phone Application,"Caregiver Activity Survey, Validated scale requires caregivers to report on amount of time spent caregiving for a particular patient. It has high test-retest reliability. Caregivers will be asked to complete this instrument once every two weeks. The scale describes the total number of minutes spent daily on six different caregiving activities. Therefore the minimum value for each item is 0 and the maximum is 1,440 for each item. Higher scores on each item mean more time spent caregiving., week 2","Zarit Caregiver Burden Scale, This is validated instrument designed to reflect what people sometimes feel when taking care of another person. Caregivers will be asked to complete this instrument once every two weeks. Total score was calculated. Scores ranged from 0-48 with a higher score indicating greater caregiver burden., Up to 6 months|AD Quality of Life Scale, Assesses Caregiver quality of life with 13 questions rating from poor to excellent. Caregivers circle their responses. Caregivers will be asked to complete this instrument once every two weeks. Total score was calculated. Scores ranged from 13-52, with a higher score indicating better quality of life in caregivers., up to 6 months","Device Accuracy, Percentage of physical checks where device displayed correct location of patient/resident. Only partners reported on the accuracy. No data were required from participants. Therefore, they were entered as 0s in the chart., First month of overall study period",University of Florida,"National Institute on Aging (NIA)|Aster Labs, Inc",ALL,"ADULT, OLDER_ADULT",NA,13,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,IRB201702352 -N -A|OCR17448|5R44AG046944-03,2021-01-27,2022-05-31,2022-05-31,2017-12-02,2023-02-08,2023-05-17,"Oak Hammock Senior Living Center, Gainesville, Florida, 32608, United States|Unversity of Florida, Gainesville, Florida, 32611, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/19/NCT03360019/Prot_SAP_000.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/19/NCT03360019/ICF_001.pdf"
NCT01958437,Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation,https://clinicaltrials.gov/study/NCT01958437,,COMPLETED,"Remembering how to travel from one location to another is critical in everyday life, yet this vital ability declines with normal aging and can be further affected by conditions that disproportionately affect the elderly, such as vision loss or progressive dementia. Human and animal research has shown that two distinct memory systems interact during navigation. The first, referred to as allocentric navigation, is very flexible and uses spatial knowledge of key features or landmarks to develop and use a mental map of the environment. This approach involves brain regions that are critical for new learning and memory but that decline with age. The second, referred to as egocentric navigation, is inflexible and relies on ""habit"" memories that link specific features with specific directions. This approach relies on brain regions that are critical for ""automatic"" responses and that are relatively unaffected by age.

The main problem is that allocentric navigation declines with age and is accompanied increased dependence on egocentric navigation. This change increases the risk of becoming disoriented or ""lost"" when traveling in unfamiliar areas or even when traveling new routes in familiar areas. Therefore, the main goal of this project is to examine whether non-invasive brain stimulation, specifically transcranial direct current stimulation, can improve allocentric navigation in healthy older adults and patients with mild cognitive impairment.

Participants will complete two functional magnetic resonance imaging sessions while learning new environments. Before one of these sessions, participants will receive active brain stimulation over the parietal cortex. Before the other session, participants will receive sham brain stimulation over the parietal cortex. The effects of this stimulation will be evaluated using both an allocentric and an egocentric memory test. Physiologic effects will be evaluated using both task-based and resting-state MRI.",YES,Mild Cognitive Impairment|Alzheimer's Disease,DEVICE: Transcranial direct current stimulation (tDCS),"Accuracy in Centimeters From Target Location for Allocentric, 1 active tDCS; 1 sham tDCS for each measure. Participants touched a screen (using a ELO 19"" touchscreen monitor) to document the location of the landmark. The distance between the actual vs. selected location served as the dependent measure., Outcome assessed after each of 2 sessions (estimated within 1 week of each other)|Hippocampal BOLD Signal During Task-based fMRI, BOLD signal change comparing active to sham tDCS during Allocentric navigation (i.e., active HD-tDCS \> sham HD-tDCS). Activation maps thresholded at p\<.01 with minimum cluster size of 5 voxels., change between active and sham tDCS sessions (<1month)|Dorsal Attention Network Connectivity During Resting-state fMRI, Change in resting state functional connectivity strength between active and sham tDCS sessions. Strength is measured by Pearson r correlations between nodes, which are z-transformed, and summated., change between active and sham tDCS sessions (<1month)|Egocentric, Number of turns correctly recalled for each egocentric environment, Outcome assessed after each of the 2 sessions",,,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",NA,44,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",C1381-P,2013-10-01,2017-03-23,2017-03-24,2013-10-09,2018-04-16,2018-08-31,"Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, 30033, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, 48105, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/37/NCT01958437/Prot_SAP_000.pdf"
NCT03876314,"Physical Activity, Alzheimer's Disease and Cognition Relative to APOE Genotype",https://clinicaltrials.gov/study/NCT03876314,PAAD-2,RECRUITING,"Physical activity and Alzheimer's disease (PAAD-2) is a randomized control trial that will assess the effects of exercise on middle-aged (40-65 years) cognitively normal adults who have a heightened risk of Alzheimer's disease (AD) due to family history (FH+). The investigators will also assess the extent to which this effect is moderated by apolipoprotein epsilon-4 (APOE4) carrier status, and will gather critical new experimental evidence on the use of physical activity to improve cognitive performance by persons at the greatest risk of Alzheimer's disease.",NO,Healthy|Dementia|Alzheimer Disease|Physical Activity,BEHAVIORAL: Physical Activity Condition,"Change in performance on the cognitive domain of executive function as measured with Stroop Interference, Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on Stroop Interference., Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of executive function as measured with Trail Making Test Interference, Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on Trail Making Test interference., Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of executive function as measured with Dimensional Change Card Sort, Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on Dimensional Change Card Sort, Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of executive function as measured with the Flanker test., Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on the Flanker test., Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of executive function as measured with Matrix Reasoning., Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on Matrix Reasoning., Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of memory as measured with the Auditory Verbal Learning Test., Change in memory will be assessed by comparing post-, mid-, and pre-test performance on the Auditory Verbal Learning Test., Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of memory as measured with the Rey-Osterrieth Complex Figure Test, Change in memory will be assessed by comparing post-, mid-, and pre-test performance on the Rey-Osterrieth Complex Figure Test, Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of memory as measured with the Picture Sequence test, Change in memory will be assessed by comparing post-, mid-, and pre-test performance on the Picture Sequence test., Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of memory as measured with the Mnemonic Similarity Test, Change in memory will be assessed by comparing post-, mid-, and pre-test performance on the Mnemonic Similarity Test, Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of attention as measured with the Paced Auditory Serial Addition Test, Change in attention will be assessed by comparing post-, mid-, and pre-test performance on the Paced Auditory Serial Addition Test, Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of attention as measured with the Forward Digit Span test, Change in attention will be assessed by comparing post-, mid-, and pre-test performance on the Forward Digit Span, Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of working memory as measured with List Sort Working Memory, Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the List Sort Working Memory, Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of working memory as measured with Spatial Working Memory, Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Spatial Working Memory, Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of working memory as measured with Backward Digit Span, Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Backward Digit Span, Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of processing speed as measured with the Wechsler Adult Intelligence Scale (WAIS-IV) Digit Symbol Task, Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Wechsler Adult Intelligence Scale (WAIS-IV) Digit Symbol Task, Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of processing speed as measured with the Stroop Color Test, Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Stroop Color Test, Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of processing speed as measured with the Stroop Word Test, Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Stroop Word Test, Pretest, 6 months, and 12 months|Change in performance on the cognitive domain of processing speed as measured with the Trail Making Test A, Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Trail Making Test A, Pretest, 6 months, and 12 months","Change in brain morphology (whole brain and hippocampal volumes), MRI will be used to measure brain morphology including whole brain and hippocampal volumes and change will be assessed from pre-test to post-test., Pretest and 12 months|Change in brain activity (resting-state connectivity), Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test., Pretest and 12 months|Change in blood biomarkers (BDNF, irisin, IGF-1, glucose, insulin, TNF-âº, serum amyloid protein (SAP), albumin, ApoE and âº-2 macroglobulin), Blood samples will be taken following a 12-hour fast. Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-âº, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and âº-2 macroglobulin. Change from pre-test to post-test will be assessed., Pretest and 12 months|Change in cardiorespiratory fitness, Fitness will be assessed using a submaximal graded aerobic exercise test performed on a treadmill. Oxygen uptake (VO2) will be measured during a ramped exercise protocol performed until volitional exhaustion or test termination due to symptom limitations. Change across time will be assessed., Pretest, 6 months, and 12 months",,"University of North Carolina, Greensboro",Wake Forest University Health Sciences|National Institute on Aging (NIA),ALL,"ADULT, OLDER_ADULT",NA,240,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",18-0228|R01AG058919,2019-05-23,2023-12,2023-12,2019-03-15,,2023-05-15,"University of North Carolina-Greensboro, Greensboro, North Carolina, 27402, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/14/NCT03876314/Prot_SAP_001.pdf"
NCT03656107,The Cognition and Flow Study,https://clinicaltrials.gov/study/NCT03656107,,TERMINATED,"About the research

There are currently 850,000 people living with dementia in the United Kingdom. It is now understand that Alzheimer's disease (AzD) can result from damaged blood vessels in the brain. Brain blood flow can be measured using ultrasound, known as transcranial Doppler ultrasonography (or TCD).

Brain training (BT) uses exercises or brain-teasers to try to make the brain work faster and more accurately. In recent years, BT has been used to try to improve memory, mood, learning, quality of life, and ability to carry out every-day activities in people with dementia.

Aims

1. To find out how acceptable and manageable this BT program is for people with dementia to undertake larger studies of BT in the future.
2. To look for any benefits for people with dementia, such as, improvements in quality of life, ability to carry out everyday tasks, mood, and brain blood flow.

How will the research be carried out?

* Forty patients with AzD, or mild cognitive impairment (MCI), and twenty healthy older adults will be recruited from memory and geriatric clinics, Join Dementia Research, general practice surgeries and community groups.
* Participants will be randomly assigned to brain training or control. The control group will be offered the program at the end of the study.
* First visit: Participants will complete questionnaires on quality of life, mood, everyday abilities, memory and an assessment of brain blood flow
* Brain training program: Participants will complete 15-30 minute sessions, 3-5 times per week
* Follow-up: participants will repeat the questionnaires and assessment of brain blood flow
* Interviews and feedback: to discuss how participants felt the program went, and find out if there are any ways it could be improved.",YES,Dementia|Alzheimer Disease|Mild Cognitive Impairment|Aging|Cognitive Impairment,BEHAVIORAL: Cognitive Training,"Percentage of Participants Successfully Recruited, Feasibility, 15 months|Percentage of Participants Able to Successfully Complete the Minimum (15 Mins, 3x Per Week, for 8 Weeks) and Maximum (30 Mins, 5x Per Week, for 12 Weeks) Criteria CT Program and Complete All Assessments, Feasibility, 17 months|Percentage of Participants With Full Bilateral Data for Cerebral Blood Flow Velocity (CBFv), Feasibility CBFv as measured using transcranial Doppler ultrsonography (TCD), 17 months|Percentage of Control Participants Willing to be Randomised to Waiting List Control, Feasibility, 17 months","Change in Cognition Score as Detected by the Addenbrooke's Cognitive Examination (ACE-III) From Baseline to Follow-up at 12 Weeks, cognitive function. Maximum score 100, minimum score 0. Sub scale scores: attention (0-18), language (0-26), fluency (0-14), visuospatial (0-16), memory (0-26). Higher score = better cognition., 12 weeks|Change in Functional Status - Lawton Instrumental Activities of Daily Living (IADL) From Baseline to Follow-up at 12 Weeks, Functional status (maximum score =8, minimum score =0). Higher score is equivalent to better function., 12 weeks|Change in Mood - Geriatric Depression Scale (GDS-15) From Baseline to Follow-up at 12 Weeks, Mood, maximum score 15, minimum score 0. Severe depression = 10-15, mild depression = 5-9, no depression = 0-4., 12 weeks|Change in Quality of Life Measure - Dementia Quality of Life Measure (DEMQOL) From Baseline to Follow-up at 12 Weeks, Quality of life, minimum score 28, maximum score 112. higher score = better quality of life., 12 weeks|Percentage Increase in Cerebral Blood Flow Velocity (CBFv) From Baseline to Follow-up at 12 Weeks, Neurovascular function as measured by task activation, TCD protocol. Continuous CBFv was measured using TCD whilst participants underwent five cognitive tasks from the ACE-III. Task activation was measured as the percentage change in CBFv from 20 second prior to the task. T2 is the percentage change at 5-10 seconds after the task and T3 is the percentage change at 10-20 seconds after the task., 12 weeks",,University of Leicester,"The Dunhill Medical Trust|University Hospitals, Leicester|Leicestershire Partnership Trust|University of Nottingham|Lumosity",ALL,"ADULT, OLDER_ADULT",NA,56,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,0677,2019-01-14,2020-09-04,2020-09-04,2018-09-04,2021-03-30,2022-05-27,"University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, LE1 5WW, United Kingdom|Leicestershire Partnership Trust, Leicester, Leicestershire, United Kingdom","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/07/NCT03656107/Prot_SAP_000.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/07/NCT03656107/ICF_001.pdf"
NCT03634033,Implementation of CAPABLE in the Michigan Medicaid Waiver,https://clinicaltrials.gov/study/NCT03634033,,COMPLETED,"Main study: Nearly half of older adults report problems with function, which can lead to difficulty with activities of daily living and nursing home placement. Thus, there is a need to implement evidence-based models of care to improve function and those factors that support function in older adults living in the community. One such model is CAPABLE (Community Aging in Place Advancing Better Living for Elders), a person-centered, nurse and occupational therapy intervention supported by assistive devices and home modifications. The investigators build on prior work that translated CAPABLE and conducted preliminary testing of a package of implementation strategies. This R15 application will test site-level adoption and sustainability after deploying a package of implementation strategies (readiness assessment, training, facilitation, champions, coalition building, and audit and feedback). Sites will be randomized to internal facilitation alone or internal facilitation plus external facilitation. This work will impact implementation science by testing two approaches to implementation of an evidence-based intervention to improve outcomes among older adults in a Medicaid Waiver program.

ADMINISTRATIVE SUPPLEMENT We extend the Parent Trial by addressing a problem found while deploying CAPABLE with beneficiaries with Alzheimer's disease (AD) or dementia. There are 39.8 million informal caregivers in the US and 16.3 million who care for someone with AD or dementia; and 1,500 of those are in the Michigan waiver. Most beneficiaries with those conditions did not accept CAPABLE as they were unable to receive instruction. Interventions that improve caregiver knowledge, confidence, and self-efficacy improve care they provide. Thus, the goal is to extend provision of CAPABLE to beneficiaries with AD or dementia via the engagement of their informal caregivers. This work is significant as there are 1,500 beneficiaries with AD or dementia in the waiver who could benefit from CAPABLE yet many did not, as they were to receive instructions. To date, CAPABLE has only been designed to be used directly with the individuals without caregiver involvement. In the waiver, beneficiaries are required to have a designated caregiver, therefore, modifying the toolkit for use by caregivers could aid in deploying CAPABLE to beneficiaries with AD or dementia.",YES,Independent Living,BEHAVIORAL: MiCAP with IF (Main Study)|BEHAVIORAL: MiCAP with IF and EF (Main Study)|BEHAVIORAL: MiCAP with IF and Caregiver Engagement (Administrative Supplement),"Main Study: Effect of MiCAP With IF Alone Versus MiCAP With IF+EF on Site-level Outcomes of Adoption and Sustainability of CAPABLE, Adoptions and sustainability of the intervention using the Stages of Implementation Completion (SIC) at a site (18). SIC is a tool that tracks achievement of key activities when implementing an evidence-based intervention.

SIC has 6 stages with multiple implementation activities; each activity had an assigned numeric value and when a activity was completed, a score was assigned. The \*total\* SIC score ranges from 0-100. Stage 1 score range 0-12. Stage 2 0-16. Stage 3 0-24. Stage 4 0-16. Stage 5 0-16. Stage 6 0-16. The \*total\* score was calculated by summing the points of each stage. The higher the \*total\* score, the more implementation activities were completed.

For the below reported \*total\* score, each waiver site had their \*total\* SIC score numerically calculated. Then, the mean and standard deviation were calculated by group/arm., 9 months","Main Study: Beneficiary's ADLs Summed Score, Activities of Daily Living (ADLs) data were collected from the Minimum Data Set-Home Care (MDS-HC) in the Electronic Health Record (EHR). MDS-HC is a person-centered assessment for the collection of minimum essential nursing data, with reliability and validity, and used in the Michigan Medicaid Waiver program.

The score is a summed score of 11 items on the MDS-HC; with a score range of 0-88. The lower the summed score, the more independent the beneficiary is at performing ADLs. For the 11 items, the available scores are 0= Independent, 1= Set-up help only, 2= Supervision, 3= Limited assistance, 4= Extensive assistance, 5= Maximal assistance, 6= Total dependence, 8= Activity did not occur during entire period., Exit (9-months)|Main Study: Beneficiary's IADLs, Instrumental Activities of Daily Living (IADLs) was collected from the Minimum Data Set-Home Care (MDS-HC) in the Electronic Health Record (EHR). MDS-HC is a person-centered assessment for the collection of minimum essential nursing data, with reliability and validity, and used in the Michigan Medicaid Waiver program.

The below reported score is a summed score of 8 items on the MDS-HC; summed score range is 0-64. The lower the summed score, the more independent the beneficiary is at performing IADLs. For the 8 items, the available scores are 0= Independent, 1= Set-up help only, 2= Supervision, 3= Limited assistance, 4= Extensive assistance, 5= Maximal assistance, 6= Total dependence, 8= Activity did not occur during entire period., Exit (9-months)|Main Study: Beneficiary's Pain, Pain data were collected from the Minimum Data Set-Home Care (MDS-HC) in the Electronic Health Record (EHR). MDS-HC is a person-centered assessment for the collection of minimum essential nursing data, with reliability and validity, and used in the Michigan Medicaid Waiver program.

The score is a summed score of 4 self-reported items on the MDS-HC; the summed score range is 0-11. The lower the summed score, the less pain the beneficiary reported. The four items included: pain frequency (range 0-3); pain intensity (0-4); pain consistency (0-3); and breakthrough pain (0-1)., Exit (9-months)|Main Study: Beneficiary's Depression, Depression was collected from the Minimum Data Set-Home Care (MDS-HC) in the Electronic Health Record (EHR). MDS-HC is a person-centered assessment for the collection of minimum essential nursing data, with reliability and validity, and used in the Michigan Medicaid Waiver program.

The below reported score is a summed score of 3 self-reported items on the MDS-HC; the summed score range is 0-24. The lower the summed score, the less depressed the beneficiary reported. The 3 items included: little interest in things; anxious, restless, or uneasy; and sad, depressed, or hopeless. For the 3 items, the available scores are 0= Not in last 3 days, 1= Not in last 3 days, but often feels that way, 2= In 1-2 days of last 3 days, 3= Daily in last 3 days, 8= Person could not (would not) respond., Exit (9-months)|Main Study: Beneficiary's Fall Rate, Beneficiary falls data were collected from the Minimum Data Set-Home Care (MDS-HC) in the Electronic Health Record. MDS-HC is a person-centered assessment for the collection of minimum essential nursing data, with reliability and validity, and used in the Michigan Medicaid Waiver program.

Falls were reported as proportions of occurrences on the MDS-HC; and calculated for this study based on the occurrence of a fall where yes=1 and no=0 divided by the number of participants., Exit (9-months)|Main Study: Beneficiary's Emergency Department (ED) Visits Occurrences Out of Total Number of Participants., Beneficiary-level outcome emergency department (ED) data were collected from the Minimum Data Set-Home Care (MDS-HC) in the Electronic Health Record. MDS-HC is a person-centered assessment for the collection of minimum essential nursing data, with reliability and validity, and used in the Michigan Medicaid Waiver program.

ED visits were reported as proportion calculated based on the occurrence of an ED visit where yes=1 and no=0 out of the number of participants., Exit (9-months)|Main Study: Beneficiary's Hospitalization Occurrences Out of Total Number of Participants., Beneficiary-level outcomes hospitalizations data were collected from the Minimum Data Set-Home Care (MDS-HC) in the Electronic Health Record. MDS-HC is a person-centered assessment for the collection of minimum essential nursing data, with reliability and validity, and used in the Michigan Medicaid Waiver program.

Hospitalizations were reported based on the occurrence and calculated for this study as rates of hospitalization where yes=1 and no=0 out of total number of participants., Exit (9-months)","Main Study: Clinician Attitude Towards Evidence Based Practice Use, Evidence-Based Practice Attitude Scale (EBPAS-50) is a 50-item tool that assesses clinician attitudes toward adopting evidence into practice. EBPAS-50 has 50 items on the tool which includes 10 sub-scales: limitations, openness, monitoring, requirements, employability, feedback, burden, appeal, divergence, balance; and the questions are negatively framed. The 10 sub-scales are summed into a higher order total scale score representing respondent's attitude toward adopting evidence into practice.

EBPAS-50 total scale score ranges from 0-200 with higher being a better attitude towards use of evidence in practice. Each of the 10 sub-scales ranges from 0-20; with higher being a better attitude towards use of evidence.

Items are reversed scored, and the mean sub-scale scores are recomputed, before a mean score for the total EBPAS-50 item score is computed.

A higher total score indicate a more positive attitude towards adoption of evidence-based practice use., Exit (9-months)|Main Study: Clinician Self-efficacy, General Self-efficacy (GSE) is a 10-item tool (Cronbach .79-.90) with a 4-point scale summed to 10-40, with a higher score indicating more self-efficacy., Exit (9-months)|Administrative Supplement: Feasibility of Use of Intervention With Clinicians, Caregivers and Beneficiaries., Feasibility of use of intervention with caregivers use of toolkit with beneficiaries with Alzheimer's Disease or dementia following implementation of CAPABLE.

Feasibility was measured as: the percentage of those who consented and enrolled of those who were recruited who were eligible., Recruitment period of 9-months.|Administrative Supplement: Acceptability of Caregiver Use of Intervention With Beneficiaries., Acceptability of Caregiver Use of Toolkit With Beneficiaries With Alzheimer's Disease or Dementia Following Implementation of CAPABLE. Acceptability: counts of toolkit use and sections used., 9-months|Administrative Supplement: Beneficiaries Outcomes Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADLs), Pain and Depression) Pre-/Post-intervention From Minimum Data Set-Home Care MDS-HC., Activities of Daily Living: 11 items each rated as 0=Independent, 1=Set-up help, 2=Supervision, 3=Limited assist, 4=Extensive assist, 5=Maximal assist, 6=Total dependence; summed score ranged 0-66; higher score=worse Activities of Daily Living

Instrumental Activities of Daily Living: 8 items each rated as 0=Independent, 1=Set-up help, 2=Supervision, 3=Limited assist, 4 Extensive assist, 5=Maximal assist, 6=Total dependence; summed score ranged 0-48; higher score=worse Instrumental Activities of Daily Living

Pain: 4 items; ranges for frequency 0-3, intensity 0-4, consistency 0-3, breakthrough 0-1; summed score ranged 0-11; lower score=less pain.

Depression: 3 items little interest in things; anxious, restless, or uneasy; and sad, depressed, or hopeless; scored as 0=Not in last 3 days, 1=Not in last 3 days, but often feels that way, 2=In 1-2 days of last 3 days, 3=Daily in last 3 days, 8=Person could/would not respond; summed score ranged 0-24; lower score=less depressed, Baseline (0-months) compared to Exit (9-months)|Administrative Supplement: Caregiver Self Efficacy and Satisfaction With Use of Intervention., Self-efficacy and satisfaction of Caregiver Use of intervention With Beneficiaries With Alzheimer's Disease or Dementia Following Implementation of CAPABLE. Efficacy effect size of intervention use on beneficiary outcomes from Parent Trial.

SELF-EFFICACY TOOL: General Self-efficacy (GSE) is a 10-item tool (Cronbach .79-.90) with a 4-point scale summed to 0-40, with a higher score indicating more or higher self-efficacy. Cronbach's alpha at baseline was .91 for the caregiver GSE.

SATISFACTION TOOL: Developed by PI and Team. There were 3-items measured on a scale of 1 to 10 (reported as individual concepts; not summed), with 10 being the highest satisfaction. Question 1 Content: How satisfied were you with the Toolkit content? (range 1-10). Question 2 Format: How satisfied were you with the format of the Toolkit? (range 1-10). Question 3 Helpfulness: How helpful was the Toolkit? (range 1-10)""., Self-efficacy: baseline (month-0) and Exit (month-4). Satisfaction: Monthly for month 0 (baseline), 1, 2, 3, 4 (exit)|Administrative Supplement: Clinician Satisfaction With Training and Use of Intervention., Clinician satisfaction with training and use of caregiver to assist with intervention. Satisfaction: was measured using a Likert scored tool evaluating level of satisfaction (scale 1-10 with 1 being poorest)., 9-months",Grand Valley State University,Michigan State University|University of Oklahoma|National Institute on Aging (NIA)|Michigan Department of Health and Human Services,ALL,"ADULT, OLDER_ADULT",NA,7777,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,1R15AG058193-01|R15AG058193-01A1S1,2019-06-06,2021-06-15,2022-06-30,2018-08-16,2022-05-26,2022-11-30,"Northeast Michigan Community Service Agency (NEMCSA), Alpena, Michigan, 49707, United States|Region 3B Area Agency on Aging/CareWell Services Southwest, Battle Creek, Michigan, 49017, United States|Region VII Area Agency on Aging, Bay City, Michigan, 48706, United States|Region 2 Area Agency on Aging, Brooklyn, Michigan, 49230, United States|Macomb-Oakland Regional Center Home Care, Inc., Clinton Township, Michigan, 48038, United States|Detroit Area Agency on Aging, Detroit, Michigan, 48207, United States|UPCAP, Escanaba, Michigan, 49829, United States|Valley Area Agency on Aging, Flint, Michigan, 48502, United States|Area Agency on Aging of Western Michigan, Inc., Grand Rapids, Michigan, 49525, United States|Senior Services, Kalamazoo, Michigan, 49001, United States|Tri-County Office on Aging, Lansing, Michigan, 48911, United States|Senior Resources, Muskegon, Michigan, 49444, United States|A&D Home Health Care, Inc., Saginaw, Michigan, 48603, United States|Region IV Area Agency on Aging, Saint Joseph, Michigan, 49085, United States|The Information Center, Taylor, Michigan, 48180, United States|Northern Lakes Community Mental Health/Northern Health Care Management, Traverse City, Michigan, 49684, United States|Area Agency on Aging of Northwest Michigan, Traverse City, Michigan, 49696, United States|The Senior Alliance, Wayne, Michigan, 48184, United States","Study Protocol and Statistical Analysis Plan: Administrative Supplement, https://storage.googleapis.com/ctgov2-large-docs/33/NCT03634033/Prot_SAP_000.pdf|Study Protocol and Statistical Analysis Plan: Main Study, https://storage.googleapis.com/ctgov2-large-docs/33/NCT03634033/Prot_SAP_001.pdf|Informed Consent Form: Main Study - Beneficiaries, https://storage.googleapis.com/ctgov2-large-docs/33/NCT03634033/ICF_002.pdf|Informed Consent Form: Main Study - Clinicians, https://storage.googleapis.com/ctgov2-large-docs/33/NCT03634033/ICF_003.pdf|Informed Consent Form: Administrative Supplement - Beneficiary LAR DPOA, https://storage.googleapis.com/ctgov2-large-docs/33/NCT03634033/ICF_004.pdf|Informed Consent Form: Administrative Supplement - Caregiver, https://storage.googleapis.com/ctgov2-large-docs/33/NCT03634033/ICF_005.pdf|Informed Consent Form: Administrative Supplement - Clinician, https://storage.googleapis.com/ctgov2-large-docs/33/NCT03634033/ICF_006.pdf"
NCT02278367,Clinical Evaluation of Flortaucipir F 18,https://clinicaltrials.gov/study/NCT02278367,,COMPLETED,"This study is designed to expand the database of flortaucipir F 18 safety and tau binding as measured by PET imaging and to provide standardized conditions for flortaucipir PET use, data collection and analysis to facilitate companion studies including, but not limited to, longitudinal studies of aging, depression, and traumatic brain injury.",YES,Alzheimer's Disease|Traumatic Brain Injury|Depression,DRUG: Flortaucipir F18|PROCEDURE: Brain PET scan,"Number of Participants With Adverse Events Related to Flortaucipir Administration, Frequency of treatment-emergent adverse events considered related to flortaucipir administration by the study investigator. Related events with a frequency \> 1.5% are reported.

(note: all treatment-emergent adverse events, regardless of relatedness designation, are reported in ""Adverse Events"" section below)., within 48 hours of drug administration|Flortaucipir PET Scan SUVr, Standard Uptake Value Ratio (SUVr) using a weighted cortical average. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain., baseline and follow-up scans",,,Avid Radiopharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE2,179,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,18F-AV-1451-A14,2014-12,2019-06-26,2019-06-26,2014-10-30,2020-07-15,2020-09-10,"Banner Alzheimer's Institute, Phoenix, Arizona, 85006, United States|Yale University, New Haven, Connecticut, 06510, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, 89106, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Center for Vital Longevity at the University of Texas at Dallas, Dallas, Texas, 75235, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/67/NCT02278367/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/67/NCT02278367/SAP_001.pdf"
NCT02843529,Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI),https://clinicaltrials.gov/study/NCT02843529,AltoidaML,COMPLETED,"The proposed study is designed to evaluate the performance of the ALTOIDAâ„¢ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings. The design of this study is guided by two overriding factors: 1) to optimize the performance of the ALTOIDAâ„¢ Neuro Motor Index (NMI) prognosis classifiers, the subjects making up the training sets must be well characterized as to their clinical diagnosis, and 2) all ALTOIDAâ„¢ tests must be performed and reproduced in real-world clinical settings.

Although there is already a large body of peer-reviewed scientific literature demonstrating that certain digital biomarker patterns are associated with certain neurologic conditions, the utilization of such tools for the evaluation of neurologic disorders is still considered an emerging science and therefore in the investigational stage. Although this protocol will report on brain patterns of certain neurologic conditions such as cognitive impairment and Alzheimer's disease, based on patterns published in peer-reviewed journals, such findings are not considered stand alone or diagnostic per se and should always be considered by the primary physician in conjunction with the patient's clinical condition. These data should only be used as additional information to add to the primary physician's diagnostic impression.",YES,Alzheimer Disease|Mild Cognitive Impairment|Memory Disorders|Cognitive Impairment|Dementia|Presymptomatic Disease,"OTHER: Altoida: neuropsychological, MRI, EEG and CSF biomarkers","Change in Diagnostic Area Under the Receiver Operating Characteristic Curve (ROC-AUC), The machine learning models capturing voice data, hands micromovements \& micro-errors, posture changes, eye tracking, visuospatial navigation micro-errors and spatio-temporal gait parameters developed for the Altoida system will be tested in this prospective cohort. Sensitivity, specificity and accuracy of the model will be tested in differential diagnosis between the study groups as well as the accuracy of prediction cognitive decline as measured by neuropsychological test battery in the MCI group., approximately 40 months follow up","Change From Baseline in Clinical Measure 1, Clinical Dementia Rating (CDR), including CDR sum of boxes (CDR-SB) and clinician's diagnostic assessment, baseline, 6, 12, 24, 36 and 42 months of follow up|Change From Baseline in Clinical Measure 2, Geriatric Depression Scale (GDS), baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Clinical Measure 3, Functional Assessment Questionnaire (FAQ), baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Clinical Measure 4, Mini Mental Status Exam (MMSE), baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Clinical Measure 5, Neuropsychiatric Inventory Questionnaire (NPI-Q), baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Clinical Measure 6, Activities of the daily life (ADL), baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Clinical Measure 7, Instrumental activities of the daily life (iADL), baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Cognitive Measure, ADAS Cog, baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Cognitive Measure, -Rey-Osterrieth Complex Figure Test (Copy), baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Cognitive Measure, Trail Making Test, baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Cognitive Measure, Digit Span Forward, baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Cognitive Measure, Category Fluency (Animals \& Vegetables), baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Cognitive Measure, Digit Span Backward, baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Cognitive Measure, Rey Osterrieth Complex Figure Test (30 minute delay), baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Cognitive Measure, Wechsler Memory Scale - Revised (WMS-R) Digit Span, baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Cognitive Measure, Wechsler Memory Scale Logical Memory, baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Cognitive Measure, Wechsler Memory Scale Paragraph Memory (Immediate \& Delayed Recall), baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Cognitive Measure, Wechsler Adult Intelligence Scale - Revised (WAIS-R) Digit-Symbol Substitution Test, baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change From Baseline in Cognitive Measure, Rey Auditory Verbal Learning Test (RAVLT), baseline, 6, 12, 24, 36 and approximately 40 months follow up|Secondary Resting State EEG Endpoints, EEG endpoints (occipital, parietal, and temporal sources of delta and low-frequency alpha rhythms) according to the PharmaCog WP5 European ADNI. These markers are expected to be related to disease status at baseline assessment and disease progression at follow-ups. Exploratory probability level of p \< 0.05., baseline, 6, 12, 24, 36 and approximately 40 months follow up|Secondary Resting State Auditory Oddball ERP Endpoints, ERP endpoints (latency of scalp parietal P3b peak and activity of the cingulate and temporal-parietal sources of P3b peak according to PharmaCog WP5 European ADNI). These markers are expected to be related to disease status at baseline assessment and disease progression at follow-ups. Exploratory probability level of p \< 0.05., baseline, 6, 12, 24, 36 and approximately 40 months follow up|Total Abeta 1-42 (AÎ²42) Amyloid Deposition, Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to abnormal processing of beta-amyloid (Abeta) peptide, ultimately leading to formation of Abeta plaques in the brain. Baseline amount of CSF Abeta(42) will be investigated., baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change of Brain Amyloid Deposition, Biomarkers of brain beta-amyloidosis are reductions in CSF Abeta(42) and increased amyloid PET tracer retention. The change in amyloid deposition as measured by Abeta 1-42 (AÎ²42) and its relation to the genetic, clinical, neuropsychological, EEG and ERP endpoints measurement will be assessed., baseline, 6, 12, 24, 36 and approximately 40 months follow up|Change of CSF Biomarkers Tau and ptau181 Values, The change in CSF biomarkers tau and ptau181 values and its relation to the genetic, clinical, neuropsychological, EEG and ERP endpoints measurement will be assessed., baseline, 6, 12, 24, 36 and approximately 40 months follow up|MRI (Optional), Relationship between MRI measures (brain volume, hippocampus atrophy, vascular lesions) and biomarkers., baseline, 6, 12, 24, 36 and approximately 40 months follow up|Changes in Driving Breaking Force, Changes in driving behavior, such as breaking force observed continuesly through in-car sensors or dongles., baseline, 6, 12, 24, 36 and approximately 40 months follow up|Changes in Driving Acceleration Velocity, Changes in driving behavior, such as acceleration velocity observed continuesly through in-car sensors or dongles., baseline, 6, 12, 24, 36 and approximately 40 months follow up|Changes in Driving Direction, Changes in driving behavior, such as sudden changes of direction observed continuesly through in-car sensors or dongles., baseline, 6, 12, 24, 36 and approximately 40 months follow up|Changes in Driving Violations, Changes in driving behavior, such as speed limit violations observed continuesly through in-car sensors or dongles., Continuous measurement for approximately 12 months follow up",,Altoida,"Greek Alzheimer's Association and Related Disorders|University of Roma La Sapienza|IRCCS Centro San Giovanni di Dio Fatebenefratelli|Neuromed IRCCS|Scripps Health|Global Brain Health Institute (GBHI)|Takeda Pharmaceuticals International, Inc.|Research Center on Computational Biomarkers (RCCBM)|BiHELab - Bioinformatics and Human Electrophysiology Lab|Fundacion Clinic per a la Recerca BiomÃ©dica|University of Dublin, Trinity College|University of Barcelona|EIT Health|Klinik Hirslanden, Zurich|Center for BrainHealth - The University of Texas at Dallas",ALL,"ADULT, OLDER_ADULT",NA,548,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC",altoidaML01,2016-10-17,2020-02-18,2020-02-21,2016-07-26,2020-09-15,2023-01-18,,"Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/29/NCT02843529/Prot_SAP_000.pdf"
NCT04118985,Compensatory Training to Support Brain Healthy Lifestyle Changes in Those at Risk for Alzheimer's Disease,https://clinicaltrials.gov/study/NCT04118985,,COMPLETED,The Researchers are trying to better understand if behavioral interventions can help improve memory compensation and engagement in healthy lifestyle behaviors in those with memory concerns but normal mental status exam.,NO,Cognitive Symptom|Pre Senile Dementia|Alzheimer Disease,BEHAVIORAL: Cognitive rehabilitation and health behavior change intervention|BEHAVIORAL: Self-implementation,"Everyday Compensation Questionnaire, self-report and informant report if an informant is available of compensatory strategy use; range 0-148 with higher scores indicating more compensatory use, baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months|Lifestyle Activities Questionnaire, self-report of cognitive activities, range 13-65 with higher scores indicating more activity, baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months|BrainHQ, Number of minutes on BrainHQ computer exercise program, baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months|Physical Activities Questionnaire, self-report of physical activity; scores include number of days per week across 7 activity types and number of minutes in each activity when completed., baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months|Mindful Attention Awareness Scale, self-report of mindfulness, range of 11-66 with higher scores indicating more mindful daily experience, baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months","Everyday Cognition, self-report of everyday functioning, range 39-156 with higher scores indicating more problems in daily functioning, baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months|Quality of Life (in aging and cognitive health), self-report of quality of life, range of 13-52 with higher scores indicating better quality of life, baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months|Psychological well-being, self-report of psychological well-being/happiness; there is a total score plus subscales of autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, self-acceptance. Each subscale has 9 items for a total of 54 items. Total scores range from 54-324 with higher scores indicating higher psychological well being. Each subscale ranges from 9-54 with higher scores indicating greater well-being on that construct., baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months|Centers for Epidemiological Studies - Depression, self-report of symptoms of depression.Range 0-60 with higher scores indicating more depression, baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months|Cognitive measure of memory, Hopkins Verbal Memory test. Staff administered standardized verbal memory task. Scores include total words recalled and total recalled after a delay with higher scores indicating greater recall, baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months|cognitive measure of executive functioning, Trailmaking test; Staff administered standardized measure of attention and executive functioning. Scores include time to complete the task (with higher scores being slower) and number of errors, baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months|cognitive measure of verbal fluency, Controlled Oral Word Association Test; Staff administered standardized measure of speed and verbal fluency. Score is number of items in one minute with higher scores indicating better functioning, baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months|cognitive measure of visual scanning speed, Symbol Digit Modalities Test; Staff administered standardize measure of speed and visual scanning. Scores indicate number of items completed in the time frame with higher scores indicating better functioning., baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months|cognitive measure of response inhibition, Stroop Color Word Test; Staff administered standardized measure of speed and response inhibition. Scores indicate number of items completed in the time limit with higher scores indicating better functioning, baseline, change from baseline at end of 10 week treatment, change from baseline at 3 months, change from baseline at 6 months",,Mayo Clinic,,ALL,"ADULT, OLDER_ADULT",NA,21,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,19-006676,2019-10-10,2020-10-30,2020-10-30,2019-10-08,,2020-11-17,"Mayo Clinic, Scottsdale, Arizona, 85259, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/85/NCT04118985/Prot_SAP_000.pdf"
NCT04468347,"Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease",https://clinicaltrials.gov/study/NCT04468347,,COMPLETED,"A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the preclinical, prodromal and dementia phases of Alzheimer's disease.",YES,Alzheimer Disease|Mild Cognitive Impairment,DRUG: Flortaucipir F18|PROCEDURE: Brain PET scan,"Flortaucipir PET Imaging (Quantitative), Flortaucipir PET cortical weighted average standardized uptake value ratio (SUVr). For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain., baseline scan|Number of Participants With Advanced AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status, Scans were visually read independently by two expert readers at the sponsor, blinded to any clinical information. Subject scans were categorized as follows: Advanced AD Scan Pattern (Ï„AD++), Moderate AD Scan Pattern (Ï„AD+), Not AD Scan Pattern (Ï„AD-). For this analysis, subjects with Advanced (Ï„AD++) scans were analyzed vs. the combined Moderate and Not AD pattern groups (Ï„AD+/Ï„AD-). Amyloid status was obtained by florbetapir or carbon-11-labeled Pittsburgh compound B (\[C-11\] PiB) PET results available from the parent AIBL study., baseline scan|Number of Participants With AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status, Scans were visually read independently by two expert readers at the sponsor, blinded to any clinical information. Subject scans were categorized as follows: Advanced AD Scan Pattern (Ï„AD++), Moderate AD Scan Pattern (Ï„AD+), Not AD Scan Pattern (Ï„AD-). For this analysis, subjects with AD Pattern scans (Advanced \[Ï„AD++\] and Moderate \[Ï„AD+\] Scan Pattern) were combined vs. the Not AD pattern group (Ï„AD-). Amyloid status was obtained by florbetapir or carbon-11-labeled Pittsburgh compound B (\[C-11\] PiB) PET results available from the parent AIBL study., baseline scan",,,Avid Radiopharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE1,89,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,18F-AV-1451-A08,2014-10,2018-02,2018-02,2020-07-13,2020-07-27,2020-09-25,,"Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/47/NCT04468347/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/47/NCT04468347/SAP_001.pdf"
NCT05374278,First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia,https://clinicaltrials.gov/study/NCT05374278,,RECRUITING,"This is a first in human study that will assess the safety and diagnostic performance of \[18F\]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD).",NO,Alzheimer Disease|Frontotemporal Dementia|Dementia,DRUG: [18F]RP-115 PET/MRI or PET/CT and MRI,"Safety of Administered dose, Each study participant will undergo a physical examination, vital signs, and ECGs prior to and after the scan and will also be monitored during the scan for adverse events. Additionally, a follow-up with the subject will be conducted 24-48 hours after \[18F\]RP-115 administration.

Outcome Measure: Any adverse events will be recorded and graded according to Common Terminology Criteria for Adverse Events., A year|Dosimetry of [18F]RP-115, Whole-body PET/MRI scan will be conducted immediately after an \[18F\]RP-115 injection and last about 3.5 hours (including breaks) in 8 healthy volunteers (male and female). Equivalent organ radiation doses will be calculated in selected organs using the dynamic PET/MRI data in order to calculate the dosimetry of the tracer.

Outcome Measure: Radiation exposure per organ as milliSievert/kg, A year|Biodistribution of [18F]RP-115, Whole-body PET/MRI scan will be conducted immediately after an \[18F\]RP-115 injection and last about 3.5 hours (including breaks) in 8 healthy volunteers (male and female). Percent injected activity (%IA) will be calculated in selected organs using the dynamic PET/MRI data in order to calculate the biodistribution of the tracer.

Outcome Measure: Percent injected activity (%Injected radioactivity) in selected organs., A year","[18F]RP-115 diagnostic performance, Sixty (90) subjects (subjects with AD, FTD, and healthy age-matched controls) will undergo a brain PET/MRI scan that will be start 30-90 minutes after an \[18F\]RP-115 injection and will last about 60-90 minutes. In selected subjects, blood sample collection via arterial catheter will be performed. Significant changes in the \[18F\]RP-115 cerebral tracer binding parameters will be used in order to identify the primary affected regions in patients with Alzheimer disease compared to healthy age-matched controls.

Outcome Measure: Radioactivity distribution volume in select organs, mCi/L, Three years",,David Wilson,Rio pharmaceuticals Inc.,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,102,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,13180640,2021-11-02,2024-11-02,2025-07-01,2022-05-16,,2023-09-18,"China Basin, UCSF, San Francisco, California, 94107, United States","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/78/NCT05374278/ICF_000.pdf"
NCT03461861,Network-Level Mechanisms for Preclinical Alzheimer's Disease Development,https://clinicaltrials.gov/study/NCT03461861,,COMPLETED,"The purpose of this project is to test the hypothesis that AGB101 low dose levetiracetam extended release formulation can reduce abnormal hyperfunctional activity in the hippocampus in normal, healthy adults. The investigators will compare the functional connectivity results after taking AGB101 or placebo.",YES,APOE 4,DRUG: AGB101 220 mg|OTHER: Placebo,"Functional Connectivity Strengths of Neural Networks, The seed-based functional connectivity strengths of the hippocampus network and the default mode network will be employed to measure the changes between AGB101 and Placebo perturbation. The functional connectivity strengths will be measured with the median of the Pearson cross-correlation coefficients over entire brain regions., 2 weeks after treatment between AGB101 and Placebo","Rey Auditory Verbal Learning Test (AVLT), Delayed Recall Scaled Integer. The Higher is the Better, Rey Auditory Verbal Learning Test (AVLT), delayed recall Scaled integer will be employed to measure the episodic memory changes before and after AGB101 treatment. The AVLT score will be recorded as a standard score. The theoretical range: min 50, max 155, the higher the better. The higher the number is, the better the memory. It is an integer number., Placebo vs AGB101 2 weeks after treatment paired t-test",,Medical College of Wisconsin,National Institute on Aging (NIA),ALL,"ADULT, OLDER_ADULT",PHASE2,26,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",PRO00031146|R21AG056882-01,2019-04-11,2021-03-31,2021-03-31,2018-03-12,2022-04-28,2023-07-03,"Froedtert & The Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/61/NCT03461861/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/61/NCT03461861/SAP_002.pdf"
NCT02386670,Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD),https://clinicaltrials.gov/study/NCT02386670,PACt-MD,UNKNOWN,"This 7-year randomized controlled trial will compare the efficacy of non-invasive brain stimulation (trans-cranial Direct Current Stimulation - tDCS) combined with cognitive remediation (CR) versus sham (""placebo"") tDCS combined with sham (""placebo"") CR in slowing down cognitive decline and preventing Alzheimer's Dementia in older persons with mild cognitive impairment or major depressive disorder with or without mild cognitive impairment.",NO,"Mild Cognitive Impairment|Major Depressive Disorder, Recurrent, In Remission|Major Depressive Disorder, Single Episode, in Full Remission",OTHER: tDCS + CR|OTHER: sham tDCS + sham CR,"Change in cognitive scores over time, Z-scores for 18 measures of 12 selected cognitive tests will be calculated based on an healthy comparison group; based on these measures, in turn, z-scores will be averaged into six z-scores for six cognitive domains (executive functioning, language, speed of processing, verbal memory, visual memory, and working memory); finally, the six domain z-scores will be averaged into a composite cognitive score, the change of which is the study primary outcome measure that will be used for H1 and H3., Approximately 4, 12, 24, 36, 48, 60 months after baseline","Percentage of subjects who remain free of MCI or dementia over time, Based on consensus conference diagnosis made according to DSM-5, Approximately 4, 12, 24, 36, 48, 60 months after baseline",,Centre for Addiction and Mental Health,"Brain Canada|Applied Health Research Centre|Queen's University|Baycrest Centre for Geriatric Care|Unity Health Toronto|Sunnybrook Health Sciences Centre|University Health Network, Toronto",ALL,"ADULT, OLDER_ADULT",NA,375,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",041-2014,2015-01,2022-06,2022-12,2015-03-12,,2021-04-22,"Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Heath Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada","Study Protocol: Version 20, https://storage.googleapis.com/ctgov2-large-docs/70/NCT02386670/Prot_000.pdf"
NCT02569398,An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia,https://clinicaltrials.gov/study/NCT02569398,EARLY,TERMINATED,"The purpose of this study is to evaluate whether treatment with atabecestat slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia.",YES,Asymptomatic Amyloid-positive,"DRUG: Atabecestat, 5 mg|DRUG: Atabecestat, 25 mg|DRUG: Placebo","Change From Baseline in Preclinical Alzheimer Cognitive Composite (PACC) Score at Endpoint (Month 24), PACC has 4 components: Free and Cued Selective Reminding Test (0 (worst)-48 (best recall); Delayed Paragraph Recall test (Range 0 (worst)-25 (best recall); Wechsler Adult Intelligence scale: (ranges 0 \[none\]-135 \[best performance\]) and Mini Mental State Examination (Range 0 \[worst\] - 30 \[best performance\]). Component scores are transformed using an established normalization method into z-scores. Each of 4 component change scores is divided by baseline sample standard deviation (SD) of that component. These z scores are summed to form the composite score. Thus, a change of 1 baseline standard deviation on each component would correspond to a 4-point change on the composite. A z-score of 0 is equal to the mean and implies how many SD higher or lower score as compared with baseline score, with increase signifying improvement., Baseline and Endpoint (Month 24)","Change From Baseline in Cognitive Function Index (CFI) Score at Endpoint (Month 24), The CFI is a modified version of the Mail-in Cognitive Function Screening Instrument, a participant- and informant-reported outcome measure developed by the Alzheimer's Disease Cooperative Study (ADCS). This assessment includes 15 questions (14 of which contribute to the total score, and 1 additional unscored item) that assess the participant's perceived ability to perform high-level functional tasks in daily-life and sense of overall cognitive functional ability. Study participants and their informants independently rate the participant's abilities. A participant-reported and an informant-reported total score is calculated which ranges from 0 to 14 (yes=1; no=0; maybe=0.5 for each question) with higher scores indicating greater impairment., Baseline and Endpoint (Month 24)|Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living - Prevention Instrument (ADCS-ADLPI) Total Score at Endpoint (Month 24), The Alzheimer's Disease Cooperative Study - Activities of Daily Living -Prevention Instrument (ADCS-ADLPI) is a functional measure composed of 18 items that includes 15 activities of daily living rated on a 4-point scale and 3 high level function items. Study participants and their informants independently rate the participant's level of ability (with no difficulty = 3, with some difficulty = 2, with a lot of difficulty = 1, did not do/don't know = 0). Informants are additionally asked to evaluate whether activities were completed less often, required more time to complete, and if any errors were made performing the task. High-level function items are rated as ""yes"" or ""no"". The scores range from 0 to 45 with higher scores indicating less impairment. The total score is the sum of the scores of the 15 activities of daily living questions (range: 0-45) with higher scores indicating less impairment., Baseline and Endpoint (Month 24)|Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Score at Endpoint (Month 24), RBANS is 20 to 25 minute battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that measure following 5 indices: (1)Attention Index, composed of Digit Span and Coding; (2)Language Index, consisting of Picture Naming and Semantic Fluency subtests; (3)Visuospatial/Construction Index, made up of Figure Copy and Line Orientation subtests; (4)Immediate Memory Index, composed of List Learning and Story Memory subtests, and (5)Delayed Memory Index, consisting of List Recall, List Recognition, Story Recall, and Figure Recall subtests. Completion of RBANS yields 5 index scores based on participant performance on various subtests, as well as a composite Total Index score for battery. Total index scores range from 40 to 160, and are normalized to a mean of 100 and standard deviation (SD) of 15. Higher scores indicate less impairment., Baseline and Endpoint (Month 24)|Change From Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score at Endpoint (Month 24), The CDR-SB is an interviewer administered scale and impairment is scored in each of categories: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. Impairment is scored on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2 and severe = 3. The 6 individual category ratings, or ""box scores"", were added together to give the CDR-Sum of Boxes which ranges from 0-18. Higher score indicates severe impairment., Baseline and Endpoint (Month 24)|Change From Baseline in Neuropsychological Assessment Battery Daily Living Tests (NABDLTs) Score at Endpoint (Month 24), The Neuropsychological Assessment Battery Daily Living Tests (NABDLTs) Score represent a series of performance based measures covering 5 domains (Attention, Memory, Language, Spatial, and Executive function). These are valid, clinically meaningful measures that objectively assess functional deficits. Participant performance scores on NAB subtests are summed, and then normalized to yield an index score. Index scores can range from less than or equal to (\< =) 55 to greater than or equal to (\> =) 145, and are normalized to a mean of 100 and standard deviation of 15. Higher scores indicate less impairment., Baseline and Endpoint (Month 24)",,"Janssen Research & Development, LLC",,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,557,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",CR107373|2015-000948-42|54861911ALZ2003,2015-10-29,2018-12-20,2018-12-20,2015-10-06,2019-12-20,2020-02-10,"Birmingham, Alabama, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Downey, California, United States|La Jolla, California, United States|Newport Beach, California, United States|Orange, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Washington, District of Columbia, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Lake Worth, Florida, United States|Melbourne, Florida, United States|Miami Beach, Florida, United States|Ocoee, Florida, United States|Orlando, Florida, United States|Ormond Beach, Florida, United States|Tampa, Florida, United States|The Villages, Florida, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Decatur, Georgia, United States|Arlington Heights, Illinois, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Elkhart, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Westwood, Kansas, United States|Lexington, Kentucky, United States|Baton Rouge, Louisiana, United States|Bangor, Maine, United States|Boston, Massachusetts, United States|Plymouth, Massachusetts, United States|Ann Arbor, Michigan, United States|Kalamazoo, Michigan, United States|Hattiesburg, Mississippi, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Amherst, New York, United States|New York, New York, United States|Orangeburg, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Syracuse, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Willow Grove, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Cordova, Tennessee, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States|Madison, Wisconsin, United States|Adelaide, Australia|Brisbane, Australia|Darlinghurst, Australia|East Gosford, Australia|Heidelberg, Australia|Herston, Australia|Subiaco, Australia|Tarren Point, Australia|Waratah, Australia|Antwerpen, Belgium|Baudour, Belgium|Brussel, Belgium|Edegem, Belgium|LiÃ¨ge, Belgium|Mons, Belgium|Gatineau, Canada|Toronto, Canada|Aalborg, Denmark|Ballerup, Denmark|KÃ¸benhavn Ã˜, Denmark|RÃ¸dovre, Denmark|Kuopio N/a, Finland|Turku, Finland|Berlin, Germany|Essen, Germany|Halle, Germany|Homburg, Germany|Kiel, Germany|Mannheim, Germany|Mittweida, Germany|Stuttgart, Germany|ULM, Germany|Chiba-shi, Japan|Fukuoka-shi, Japan|Hachioji-shi, Japan|Iizuka-shi, Japan|Osaka-shi, Japan|Shibuya-ku, Japan|Shinjuku-ku, Japan|Shirakawa, Japan|Tokyo, Japan|Chihuahua, Mexico|Monterrey, Mexico|San Luis Potosi, Mexico|Tlalnepantla de Baz, Mexico|Amsterdam, Netherlands|Breda, Netherlands|s-Hertogenbosch, Netherlands|Utrecht, Netherlands|Barcelona, Spain|Getxo, Spain|Madrid, Spain|Manresa, Spain|San Sebastian, Spain|Terrassa, Spain|Valencia, Spain|MÃ¶lndal, Sweden|Birmingham, United Kingdom|Glasgow, United Kingdom|Guildford, United Kingdom|London, United Kingdom|Newcastle upon Tyne, United Kingdom|Plymouth, United Kingdom|Swindon, United Kingdom","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/98/NCT02569398/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/98/NCT02569398/SAP_001.pdf"
